

09/117921

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING NATIONAL PHASE OF
PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495

To: Asst. Commissioner of Patents
 and Trademarks
 Washington, D.C. 20231

(Our Deposit Account No. 03-3975)

(Our Order No. 20263/255164
C# / M#

TRANSMITTAL LETTER TO THE UNITED STATES
 DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: PM 255164 /
M# /Client Ref.

From: Pillsbury Madison & Sutro LLP, IP Group: Date: August 6, 1998

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

1. International Application	2. International Filing Date	3. Earliest Priority Date Claimed
<u>PCT/US97/02187</u> <u>↑ country code</u>	06 FEB 1997 Day MONTH Year	06 FEB 1996 Day MONTH Year (use item 2 if no earlier priority)

4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

(a) 20 months from above item 3 date (b) 30 months from above item 3 date,

(c) Therefore, the due date (unextendable) is August 6, 1998

5. Title of Invention PRODUCTION OF HYDROXYLATED FATTY ACIDS IN GENETICALLY MODIFIED PLANTS

6. Inventor(s) BROUN, Pierre et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. Please immediately start national examination procedures (35 U.S.C. 371 (f)).
8. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:
 - a. Request;
 - b. Abstract;
 - c. 102 pgs. Spec. and Claims;
 - d. 15 sheet(s) Drawing which are informal formal of size A4 13" 14"
9. A copy of the International Application has been transmitted by the International Bureau.
10. A translation of the International Application into English (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith including: (1) Request; (2) Abstract;
 (3) _____ pgs. Spec. and Claims;
 (4) _____ sheet(s) Drawing which are:
 informal formal of size A4 11"
 - b. is not required, as the application was filed in English.
 - c. is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
 - d. Translation verification attached (not required now).

11. **PLEASE AMEND** the specification before its first line by inserting as a separate paragraph:
- This application is the national phase of international application PCT/ US97 / 02187 filed February 6, 1997 which designated the U.S.--
 - This application also claims the benefit of U.S. Provisional Application No. 60/ _____, filed _____ .--
12. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., before 18th month from first priority date above in item 3, are transmitted herewith (file if in English but, if in foreign language, file only if not transmitted by the International Bureau) including:
13. PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau
14. Translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of **claim amendments** made before 18th month, is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).
15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
- is submitted herewith Original Facsimile/Copy
 - is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
16. **An International Search Report (ISR):**
- Was prepared by European Patent Office Japanese Patent Office Other
 - has been transmitted by the international Bureau to PTO.
 - copy herewith (1 pg(s).) plus Annex of family members (_____ pg(s).).
17. **International Preliminary Examination Report (IPER):**
- has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
 - copy herewith in English.
 - 1 IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
 - 2 Specification/claim pages # _____ claims # Dwg Sheets #
 - Translation of Annex(es) to IPER (required by 30th month due date, or else annexed amendments will be considered canceled).
18. **Information Disclosure Statement including:**
- Attached Form PTO-1449 listing documents
 - Attached copies of documents listed on Form PTO-1449
 - A concise explanation of relevance of ISR references is given in the ISR.
19. **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.
20. Copy of Power to IA agent.
21. **Drawings:** _____ sheet(s) per set: 1 set informal; Formal of size A4 11"
22. _____ (No.) **Verified Statement(s)** establishing "small entity" status under Rules 9 & 27
23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) United States of:
- | <u>Application No.</u> | <u>Filing Date</u> | <u>Application No.</u> | <u>Filing Date</u> |
|------------------------|--------------------|------------------------|--------------------|
| (1) <u>08/597,313</u> | 06 FEB 1996 | (2) _____ | _____ |
| (3) _____ | _____ | (4) _____ | _____ |
| (5) _____ | _____ | (6) _____ | _____ |
- See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
 - Copy of Form PCT/IB/304 attached.

24. Attached:

25. Preliminary Amendment:

25.5 Per Item 17.c3, cancel original pages #_____, claims #_____, Drawing Sheets #26. Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:based on amended claim(s) per above item(s) 12, 14, 17, 25, 25.5 (hilite)

Total Effective Claims	34	minus 20 =	14	x \$22/\$11 =	\$308	966/967
Independent Claims	2	minus 3 =	0	x \$82/\$41 =	\$	964/965
If any proper (ignore improper) Multiple Dependent claim is present,				add\$270/\$135 +		968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→BASIC FEE REQUIRED, NOW→→A. If country code letters in item 1 are not "US", "BR", "BB", "TT", "MX", "IL" or "NZ"

See item 16 re:

- | | | | |
|----|---|------------------|---------|
| 1. | Search Report was <u>not prepared by EPO or JPO</u> ----- | add\$1070/\$535 | 960/961 |
| 2. | Search Report was prepared by EPO or JPO ----- | add\$930/\$465 + | 970/971 |

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US", "BR", "BB", "TT", "MX", "IL" or "NZ"

- | | | | | |
|----------------------------|---|--|------------------|---------|
| → <input type="checkbox"/> | B. If neither international search fee nor international preliminary examination fee was paid to <u>USPTO</u> , ----- | add\$1070/\$535 + | 960/961 | |
| (X) | | | | |
| (only) | | | | |
| (one) | <input type="checkbox"/> | C. If international search fee was paid to <u>USPTO</u> but not international preliminary examination fee, ----- | add\$790/\$395 + | 958/959 |
| (of) | | | | |
| (these) | | | | |
| (4) | <input type="checkbox"/> | D. If international preliminary examination fee was paid to <u>USPTO</u> ----- | add\$720/\$360 + | 956/957 |
| (boxes) | | | | |
| → <input type="checkbox"/> | E. If international preliminary examination fee was paid to <u>USPTO</u> and Rules 492(a)(4) and 496(b) <u>satisfied</u> ,----- | add \$98/\$49 +98 | 962/963 | |

27. **SUBTOTAL = \$406**28. If Assignment box 19 above is X'd, add Assignment Recording fee of ----\$4040.00 +0 (581)29. Attached is a check to cover the ----- **TOTAL FEES \$406**

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached.

This **CHARGE STATEMENT** does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed

**Pillsbury Madison & Sutro LLP
Intellectual Property Group**

1100 New York Avenue, N.W. Ninth Floor East Tower Washington, D.C. 20005-3918 Tel: (202) 861-3000 Atty/Sec: PNK/sdm	By: Atty: <u>Paul N. Kokulis</u> Sig: <u>Paul N. Kokulis</u>	Reg. No. <u>16773</u> Fax: (202) 822-0944 Tel: (202) 861-3503
---	---	---

NOTE: File in duplicate with 2 postcard receipts (PAT-103) & attachments.

PRODUCTION OF HYDROXYLATED FATTY ACIDS
IN GENETICALLY MODIFIED PLANTS

TECHNICAL FIELD

The present invention concerns the identification of nucleic acid sequences and constructs, and methods related thereto, and the use of these sequences and constructs to produce genetically modified plants for the purpose of altering the fatty acid composition of plant oils, waxes and related compounds.

DEFINITIONS

The subject of this invention is a class of enzymes that introduce a hydroxyl group into several different fatty acids resulting in the production of several different kinds of hydroxylated fatty acids. In particular, these enzymes catalyze hydroxylation of oleic acid to 12-hydroxy oleic acid and icosenoic acid to 14-hydroxy icosenoic acid. Other fatty acids such as palmitoleic and erucic acids may also be substrates. Since it is not possible to refer to the enzyme by reference to a unique substrate or product, the enzyme is referred throughout as kappa hydroxylase to indicate that the enzyme introduces the hydroxyl three carbons distal (i.e., away from the carboxyl carbon of the acyl chain) from a double bond located near the center of the acyl chain.

The following fatty acids are also the subject of this invention: ricinoleic acid, 12-hydroxyoctadec-*cis*-9-enoic acid (12OH-18:1^{cis,9}) ; lesquerolic acid, 14-hydroxy-*cis*-11-icosenoic acid (14OH-20:1^{cis,11}) ; densipolic acid, 12-hydroxyoctadec-*cis*-9,15-dienoic acid (12OH-18:2^{cis,9,15}) ; auricolic acid, 14-hydroxy-*cis*-11,17-icosadienoic acid (14OH-

20:2^{cis11,17}); hydroxyerucic, 16-hydroxydocos-cis-13-enoic acid (16OH-22:1^{cis13}); hydroxypalmitoleic, 12-hydroxyhexadec-cis-9-enoic (12OH-16:1^{cis9}); icosenoic acid (20:1^{cis11}). It will be noted that icosenoic acid
5 is spelled eicosenoic acid in some countries.

BACKGROUND

Extensive surveys of the fatty acid composition of seed oils from different species of higher plants have resulted in the identification of
10 at least 33 structurally distinct monohydroxylated plant fatty acids, and 12 different polyhydroxylated fatty acids that are accumulated by one or more plant species (reviewed by van de Loo et al., 1993). Ricinoleic acid, the principal constituent of the
15 seed oil from the castor plant *Ricinus communis* (L.), is of commercial importance. The present inventors have cloned a gene from this species that encodes a fatty acid hydroxylase, and have used this gene to produce ricinoleic acid in transgenic plants
20 of other species. Some of this scientific evidence has been published by the present inventors (van de Loo et al., 1995).

The use of the castor hydroxylase gene to also produce other hydroxylated fatty acids such as
25 lesquerolic acid, densipolic acid, hydroxypalmitoleic, hydroxyerucic and auricolic acid in transgenic plants is the subject of this invention. In addition, the identification of a gene encoding a homologous hydroxylase from *Lesquerella fendleri*, and the use of this gene to produce these hydroxylated fatty acids in transgenic plants is the
30 subject of this invention.

Castor is a minor oilseed crop. Approximately 50% of the seed weight is oil (triacylglycerol) in which 85-90% of total fatty acids are the hydroxylated fatty acid, ricinoleic acid. Oil pressed or extracted from castor seeds has many industrial uses based upon the properties endowed by the hydroxylated fatty acid. The most important uses are production of paints and varnishes, nylon-type synthetic polymers, resins, lubricants, and cosmetics (Atsmon, 1989).

In addition to oil, the castor seed contains the extremely toxic protein ricin, allergenic proteins, and the alkaloid ricinine. These constituents preclude the use of the untreated seed meal (following oil extraction) as a livestock feed, normally an important economic aspect of oilseed utilization. Furthermore, with the variable nature of castor plants and a lack of investment in breeding, castor has few favorable agronomic characteristics.

For a combination of these reasons, castor is no longer grown in the United States and the development of an alternative domestic source of hydroxylated fatty acids would be attractive. The production of ricinoleic acid, the important constituent of castor oil, in an established oilseed crop through genetic engineering would be a particularly effective means of creating a domestic source.

Because there is no practical source of lesquerolic, densipolic and auricolic acids from plants that are adapted to modern agricultural practices, there is currently no large-scale use of these fatty acids by industry. However, the fatty

acids would have uses similar to those of ricinoleic acid if they could be produced in large quantities at comparable cost to other plant-derived fatty acids (Smith, 1985).

5 Plant species, such as certain species in the genus *Lesquerella*, that accumulate a high proportion of these fatty acids, have not been domesticated and are not currently considered a practical source of fatty acids (Hirsinger, 1989). This invention
10 represents a useful step toward the eventual production of these and other hydroxylated fatty acids in transgenic plants of agricultural importance.

15 The taxonomic relationships between plants having similar or identical kinds of unusual fatty acids have been examined (van de Loo et al., 1993). In some cases, particular fatty acids occur mostly or solely in related taxa. In other cases there does not appear to be a direct link between taxonomic
20 relationships and the occurrence of unusual fatty acids. In this respect, ricinoleic acid has now been identified in 12 genera from 10 families (reviewed in van de Loo et al., 1993). Thus, it appears that the ability to synthesize hydroxylated fatty acids
25 has evolved several times independently during the radiation of the angiosperms. This suggested to us that the enzymes which introduce hydroxyl groups into fatty acids arose by minor modifications of a related enzyme.

30 Indeed, as shown herein, the sequence similarity between $\Delta 12$ fatty acid desaturases and the kappa hydroxylase from castor is so high that it is not possible to unambiguously determine whether a particular enzyme is a desaturase or a hydroxylase

on the basis of evidence in the scientific literature. Similarly, a patent application (PCT WO 94/11516) that purports to teach the isolation and use of $\Delta 12$ fatty acid desaturases does not teach how 5 to distinguish a hydroxylase from a desaturase. In view of the importance of being able to distinguish between these activities for the purpose of genetic engineering of plant oils, the utility of that application is limited to the several instances 10 where direct experimental evidence (e.g., altered fatty acid composition in transgenic plants) was presented to support the assignment of function. A method for distinguishing between fatty acid desaturases and fatty acid hydroxylases on the basis 15 of amino acid sequence of the enzyme is also a subject of this invention.

A feature of hydroxylated or other unusual fatty acids is that they are generally confined to seed triacylglycerols, being largely excluded from 20 the polar lipids by unknown mechanisms (Battey and Ohlrogge 1989; Prasad et al., 1987). This is particularly intriguing since diacylglycerol is a precursor of both triacylglycerol and polar lipid. With castor microsomes, there is some evidence that 25 the pool of ricinoleoyl-containing polar lipid is minimized by a preference of diacylglycerol acyltransferase for ricinoleate-containing diacylglycerols (Bafor et al., 1991). Analyses of vegetative tissues have generated few reports of 30 unusual fatty acids, other than those occurring in the cuticle. The cuticle contains various hydroxylated fatty acids which are interesterified to produce a high molecular weight polyester which serves a structural role. A small number of other

exceptions exist in which unusual fatty acids are found in tissues other than the seed.

The biosynthesis of ricinoleic acid from oleic acid in the developing endosperm of castor (*Ricinus communis*) has been studied by a variety of methods. Morris (1967) established in double-labeling studies that hydroxylation occurs directly by hydroxyl substitution rather than via an unsaturated-, keto- or epoxy-intermediate.

Hydroxylation using oleoyl-CoA as precursor can be demonstrated in crude preparations or microsomes, but activity in microsomes is unstable and variable, and isolation of the microsomes involved a considerable, or sometimes complete loss of activity (Galliard and Stumpf, 1966; Moreau and Stumpf, 1981). Oleic acid can replace oleoyl-CoA as a precursor, but only in the presence of CoA, Mg²⁺ and ATP (Galliard and Stumpf, 1966) indicating that activation to the acyl-CoA is necessary. However, no radioactivity could be detected in ricinoleoyl-CoA (Moreau and Stumpf, 1981). These and more recent observations (Bafor et al., 1991) have been interpreted as evidence that the substrate for the castor oleate hydroxylase is oleic acid esterified to phosphatidylcholine or another phospholipid.

The hydroxylase is sensitive to cyanide and azide, and dialysis against metal chelators reduces activity, which could be restored by addition of FeSO₄, suggesting iron involvement in enzyme activity (Galliard and Stumpf, 1966). Ricinoleic acid synthesis requires molecular oxygen (Galliard and Stumpf, 1966; Moreau and Stumpf 1981) and requires NAD(P)H to reduce cytochrome b5 which is thought to be the intermediate electron donor for the

hydroxylase reaction (Smith et al., 1992). Carbon monoxide does not inhibit hydroxylation, indicating that a cytochrome P450 is not involved (Galliard and Stumpf, 1966; Moreau and Stumpf 1981). Data from a study of the substrate specificity of the hydroxylase show that all substrate parameters (i.e., chain length and double bond position with respect to both ends) are important; deviations in these parameters caused reduced activity relative to oleic acid (Howling et al., 1972). The position at which the hydroxyl was introduced, however, was determined by the position of the double bond, always being three carbons distal. Thus, the castor acyl hydroxylase enzyme can produce a family of different hydroxylated fatty acids depending on the availability of substrates. Thus, as a matter of convenience, the enzyme is referred throughout this specification as a kappa hydroxylase (rather than an oleate hydroxylase) to indicate the broad substrate specificity.

The castor kappa hydroxylase has many superficial similarities to the microsomal fatty acyl desaturases (Browse and Somerville, 1991). In particular, plants have a microsomal oleate desaturase active at the $\Delta 12$ position. The substrate of this enzyme (Schmidt et al., 1993) and of the hydroxylase (Bafor et al., 1991) appears to be a fatty acid esterified to the *sn*-2 position of phosphatidylcholine. When oleate is the substrate, the modification occurs at the same position ($\Delta 12$) in the carbon chain, and requires the same cofactors, namely electrons from NADH via cytochrome *b*₅ and molecular oxygen. Neither enzyme is inhibited

by carbon monoxide (Moreau and Stumpf, 1981), the characteristic inhibitor of cytochrome P450 enzymes.

There do not appear to have been any published biochemical studies of the properties of 5 the hydroxylase enzyme(s) in *Lesquerella*.

Conceptual basis of the invention

The present inventors have described the use of a cDNA clone from castor for the production of ricinoleic acid in transgenic plants. As noted 10 above, biochemical studies had suggested that the castor hydroxylase may not have strict specificity for oleic acid but would also catalyze hydroxylation of other fatty acids such as icosenoic acid (20:1^{cis}₁₁) (Howling et al., 1972). Based on these 15 studies, expression of kappa hydroxylase in transgenic plants of species such as *Brassica napus* and *Arabidopsis thaliana* that accumulate fatty acids such as icosenoic acid (20:1^{cis}₁₁) and erucic acid (13-docosenoic acid; 22:1^{cis}₁₃) may cause the 20 accumulation of hydroxylated derivatives of these fatty acids due to the activity of the hydroxylase on these fatty acids. Direct evidence is presented in Example 1 that hydroxylated derivatives of ricinoleic, lesquerolic, densipolic and auricolic 25 fatty acids are produced in transgenic *Arabidopsis* plants.

Example 2 shows the isolation of a novel kappa hydroxylase gene from *Lesquerella fendleri*.

In view of the high degree of sequence 30 similarity between Δ12 fatty acid desaturases and the castor hydroxylase (van de Loo et al., 1995), the validity of claims (e.g., PCT WO 94/11516) for using a limited set of desaturase or hydroxylase

genes or sequences derived therefrom to identify genes of identical function from other species must be viewed with skepticism. In this application, the present inventors teach a method by which

5 hydroxylase genes can be distinguished from desaturases. The present inventors describe a mechanistic basis for the similar reaction mechanisms of desaturases and hydroxylases. Briefly, the available evidence suggests that fatty acid

10 desaturases have a similar reaction mechanism to the bacterial enzyme methane monooxygenase which catalyses a reaction involving oxygen-atom transfer ($\text{CH}_4 \rightarrow \text{CH}_3\text{OH}$) (van de Loo et al., 1993). The cofactor in the hydroxylase component of methane

15 monooxygenase is termed a μ -oxo bridged diiron cluster (FeOFe). The two iron atoms of the FeOFe cluster are liganded by protein-derived nitrogen or oxygen atoms, and are tightly redox-coupled by the covalently-bridging oxygen atom. The FeOFe cluster

20 accepts two electrons, reducing it to the diferrrous state, before oxygen binding. Upon oxygen binding, it is likely that heterolytic cleavage also occurs, leading to a high valent oxoiron reactive species that is stabilized by resonance rearrangements

25 possible within the tightly coupled FeOFe cluster. The stabilized high-valent oxoiron state of methane monooxygenase is capable of proton extraction from methane, followed by oxygen transfer, giving methanol. The FeOFe cofactor has been shown to be

30 directly relevant to plant fatty acid modifications by the demonstration that castor stearoyl-ACP desaturase contains this type of cofactor (Fox et al., 1993).

On the basis of the foregoing considerations, the present inventors suggest that the castor oleate hydroxylase might be a structurally modified fatty acyl desaturase, based upon three arguments. The 5 first argument involves the taxonomic distribution of plants containing ricinoleic acid. Ricinoleic acid has been found in 12 genera of 10 families of higher plants (reviewed in van de Loo et al., 1993). Thus, plants in which ricinoleic acid occurs are 10 found throughout the plant kingdom, yet close relatives of these plants do not contain the unusual fatty acid. This pattern suggests that the ability to synthesize ricinoleic acid has arisen (and been lost) several times independently, and is therefore 15 has recently diverged. In other words, the ability to synthesize ricinoleic acid has evolved rapidly, suggesting that a relatively minor genetic change in the structure of the ancestral enzyme was necessary to accomplish it.

20 The second argument is that many biochemical properties of castor kappa hydroxylase are similar to those of the microsomal desaturases, as discussed above (e.g., both preferentially act on fatty acids esterified to the sn-2 position of phosphatidylcholine, both use cytochrome b5 as an intermediate electron donor, both are inhibited by cyanide, both require molecular oxygen as a substrate, both are thought to be located in the endoplasmic reticulum).

25 30 The third argument stems from the discussion of oxygenase cofactors above, in which it is suggested that the plant membrane bound fatty acid desaturases may have a μ -oxo bridged diiron cluster-type cofactor, and that such cofactors are capable

of catalyzing both fatty acid desaturations and hydroxylations, depending upon the electronic and structural properties of the protein active site.

Taking these three arguments together, the
5 present inventors suggest that kappa hydroxylase of castor endosperm is homologous to the microsomal oleate $\Delta 12$ desaturase found in all plants. A number of genes encoding microsomal $\Delta 12$ desaturases from various species have recently been cloned (Okuley et al., 1994) and substantial information about the
10 structure of these enzymes is now known (Shanklin et al., 1994). Hence, in the following invention, the present inventors teach how to use structural information to isolate and identify kappa
15 hydroxylase genes. This example teaches the method by which any carbon-monoxide insensitive plant fatty acyl hydroxylase gene can be identified by one skilled in the art.

An unpredicted outcome of our studies on the
20 castor hydroxylase gene in transgenic *Arabidopsis* plants was the discovery that expression of the hydroxylase leads to increased accumulation of oleic acid in seed lipids. Because of the low nucleotide sequence homology between the castor hydroxylase and
25 the $\Delta 12$ -desaturase (about 67%), it is unlikely that this effect is due to silencing (also called sense-suppression or cosuppression) of the expression of the desaturase gene by the hydroxylase gene. Whatever the basis for the effect, this invention
30 teaches the use of hydroxylase genes to alter the level of fatty acid unsaturation in transgenic plants. This invention also teaches the use of genetically modified hydroxylase and desaturase

genes to achieve directed modification of fatty acid unsaturation levels.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-D show the mass spectra of hydroxy fatty acids standards (Figure 1A, O-TMS-methylricinoleate; Figure 1B, O-TMS-methyl densipoleate; Figure 1C, O-TMS-methyl-lesqueroleate; and Figure 1D, O-TMS-methylauricoleate).

Figure 2 shows the fragmentation pattern of trimethylsilylated methyl esters of hydroxy fatty acids.

Figure 3A shows the gas chromatogram of fatty acids extracted from seeds of wild type *Arabidopsis* plants. Figure 3B shows the gas chromatogram of fatty acids extracted from seeds of transgenic *Arabidopsis* plants containing the fah12 hydroxylase gene. The numbers indicate the following fatty acids: [1] 16:0; [2] 18:0; [3] 18:1^{cisΔ9}; [4] 18:2^{cisΔ9,12}; [5] 20:0; [6] 20:1^{cisΔ11}; [7] 18:3^{cisΔ9,12,15}; [8] 20:2^{cisΔ11,14}; [9] 22:1^{cisΔ13}; [10] ricinoleic acid; [11] densipolic acid; [12] lesquerolic acid; and [13] auricolic acid.

Figures 4A-D show the mass spectra of novel fatty acids found in seeds of transgenic plants. Figure 4A shows the mass spectrum of peak 10 from Figure 3B. Figure 4B shows the mass spectrum of peak 11 from Figure 3B. Figure 4C shows the mass spectrum of peak 12 from Figure 3B. Figure 4D shows the mass spectrum of peak 13 from Figure 3B.

Figure 5 shows the nucleotide sequence of pLesq2 (SEQ ID NO:1).

Figure 6 shows the nucleotide sequence of pLesq3 (SEQ ID NO:2).

Figure 7 shows a Northern blot of total RNA from seeds of *L. fendleri* probed with pLesq2 or pLesq3. S, indicates RNA is from seeds; L, indicates RNA is from leaves.

5 Figures 8A-B show the nucleotide sequence of genomic clone encoding pLesq-HYD (SEQ ID NO:3), and the deduced amino acid sequence of hydroxylase enzyme encoded by the gene (SEQ ID NO:4).

10 Figures 9A-B show multiple sequence alignment of deduced amino acid sequences for kappa hydroxylases and microsomal Δ12 desaturases.

Abbreviations are: Rcfah12, fah12 hydroxylase gene from *R. communis* (van de Loo et al., 1995); Lffah12, 15 kappa hydroxylase gene from *L. fendleri*; Atfad2, fad2 desaturase from *Arabidopsis thaliana* (Okuley et al., 1994); Gmfad2-1, fad2 desaturase from *Glycine max* (GenBank accession number L43920); Gmfad2-2, fad2 desaturase from *Glycine max* (Genbank accession number L43921); Zmfad2, fad2 desaturase from *Zea mays* (PCT WO 94/11516); Rcfad2, fragment of fad2 desaturase from *R. communis* (PCT WO 94/11516); Bnfad2, fad2 desaturase from *Brassica napus* (PCT WO 94/11516); LFFAH12.AMI, SEQ ID NO:4; FAH12.AMI, SEQ ID NO:5; ATFAD2.AMI, SEQ ID NO:6; BNFAD2.AMI, SEQ ID NO:7; GMFAD2-1.AMI, SEQ ID NO:8; GMFAD2-2.AMI, SEQ ID NO:9; ZMFAD2.AMI, SEQ ID NO:10; and RCFAD2.AMI, SEQ ID NO:11.

30 Figure 10 shows a Southern blot of genomic DNA from *L. fendleri* probed with pLesq-HYD. E = EcoRI, H = HindIII, X = XbaI.

Figure 11 shows a map of binary Ti plasmid pSLJ44024.

Figure 12 shows a map of plasmid pYES2.0

Figure 13 shows part of a gas chromatogram of derivatized fatty acids from yeast cells that contain plasmid pLesqYes in which expression of the hydroxylase gene was induced by addition of galactose to the growth medium. The arrow points to a peak that is not present in uninduced cells. The lower part of the figure is the mass spectrum of the peak indicated by the arrow.

SUMMARY OF THE INVENTION

This invention relates to plant fatty acyl hydroxylases. Methods to use conserved amino acid or nucleotide sequences to obtain plant fatty acyl hydroxylases are described. Also described is the use of cDNA clones encoding a plant hydroxylase to produce a family of hydroxylated fatty acids in transgenic plants.

In a first embodiment, this invention is directed to recombinant DNA constructs which can provide for the transcription, or transcription and translation (expression) of the plant kappa hydroxylase sequence. In particular, constructs which are capable of transcription, or transcription and translation in plant host cells are preferred. Such constructs may contain a variety of regulatory regions including transcriptional initiation regions obtained from genes preferentially expressed in plant seed tissue. In a second aspect, this invention relates to the presence of such constructs in host cells, especially plant host cells which have an expressed plant kappa hydroxylase therein.

In yet another aspect, this invention relates to a method for producing a plant kappa hydroxylase in a host cell or progeny thereof via the expression

of a construct in the cell. Cells containing a plant kappa hydroxylase as a result of the production of the plant kappa hydroxylase encoding sequence are also contemplated herein.

5 In another embodiment, this invention relates to methods of using a DNA sequence encoding a plant kappa hydroxylase for the modification of the proportion of hydroxylated fatty acids produced within a cell, especially plant cells. Plant cells
10 having such a modified hydroxylated fatty acid composition are also contemplated herein.

In a further aspect of this invention, plant kappa hydroxylase proteins and sequences which are related thereto, including amino acid and nucleic
15 acid sequences, are contemplated. Plant kappa hydroxylase exemplified herein includes a *Lesquerella fendleri* fatty acid hydroxylase. This exemplified fatty acid hydroxylase may be used to obtain other plant fatty acid hydroxylases of this
20 invention.

In a further aspect of this invention, a nucleic acid sequence which directs the seed specific expression of an associated polypeptide coding sequence is described. The use of this
25 nucleic acid sequence or fragments derived therefrom, to obtain seed-specific expression in higher plants of any coding sequence is contemplated herein.

In a further aspect of this invention, the
30 use of genes encoding fatty acyl hydroxylases of this invention are used to alter the amount of fatty acid unsaturation of seed lipids. The present invention further discloses the use of genetically modified hydroxylase and desaturase genes to achieve

directed modification of fatty acid unsaturation levels.

DETAILED DESCRIPTION OF THE INVENTION

- A genetically transformed plant of the present invention which accumulates hydroxylated fatty acids can be obtained by expressing the double-stranded DNA molecules described in this application.
- A plant fatty acid hydroxylase of this invention includes any sequence of amino acids, such as a protein, polypeptide or peptide fragment, or nucleic acid sequences encoding such polypeptides, obtainable from a plant source which demonstrates the ability to catalyze the production of ricinoleic, lesquerolic, hydroxyerucic (16-hydroxydocos-cis-13-enoic acid) or hydroxypalmitoleic (12-hydroxyhexadec-cis-9-enoic) from CoA, ACP or lipid-linked monoenoic fatty acid substrates under plant enzyme reactive conditions.
- By "enzyme reactive conditions" is meant that any necessary conditions are available in an environment (i.e., such factors as temperature, pH, lack of inhibiting substances) which will permit the enzyme to function.
- Preferential activity of a plant fatty acid hydroxylase toward a particular fatty acyl substrate is determined upon comparison of hydroxylated fatty acid product amounts obtained per different fatty acyl substrates. For example, by "oleate preferring" is meant that the hydroxylase activity of the enzyme preparation demonstrates a preference for oleate-containing substrates over other substrates.
- Although the precise substrate of the castor fatty

acid hydroxylase is not known, it is thought to be a monounsaturated fatty acid moiety which is esterified to a phospholipid such as phosphatidylcholine. However, it is also possible 5 that monounsaturated fatty acids esterified to phosphatidylethanolamine, phosphatidic acid or a neutral lipid such as diacylglycerol or a Coenzyme-A thioester may also be substrates.

As noted above, significant activity has been 10 observed in radioactive labelling studies using fatty acyl substrates other than oleate (Howling et al., 1972) indicating that the substrate specificity is for a family of related fatty acyl compounds. Because the castor hydroxylase introduces hydroxy 15 groups three carbons from a double bond, proximal to the methyl carbon of the fatty acid, the enzyme is termed a kappa hydroxylase for convenience. Of particular interest, the present invention discloses that the castor kappa hydroxylase may be used for 20 production of 12-hydroxy-9-octadecenoic acid (ricinoleate), 12-hydroxy-9-hexadecenoic acid, 14-hydroxy-11-eicosenoic acid, 16-hydroxy-13-docosenoic acid, 9-hydroxy-6-octadecenoic acid by expression in plants species which produce the non-hydroxylated 25 precursors. The present invention also discloses production of additionally modified fatty acids such as 12-hydroxy-9,15-octadecadienoic acid that result from desaturation of hydroxylated fatty acids (e.g., 12-hydroxy-9-octadecenoic acid in this example).

30 The present invention also discloses that future advances in the genetic engineering of plants will lead to production of substrate fatty acids, such as icosenoic acid esters, and palmitoleic acid esters in plants that do not normally accumulate

such fatty acids. The invention described herein may be used in conjunction with such future improvements to produce hydroxylated fatty acids of this invention in any plant species that is amenable to 5 directed genetic modification. Thus, the applicability of this invention is not limited in our conception only to those species that currently accumulate suitable substrates.

As noted above, a plant kappa hydroxylase of 10 this invention will display activity towards various fatty acyl substrates. During biosynthesis of lipids in a plant cell, fatty acids are typically covalently bound to acyl carrier protein (ACP), coenzyme A (CoA) or various cellular lipids. Plant 15 kappa hydroxylases which display preferential activity toward lipid-linked acyl substrate are especially preferred because they are likely to be closely associated with normal pathway of storage lipid synthesis in immature embryos. However, 20 activity toward acyl-CoA substrates or other synthetic substrates, for example, is also contemplated herein.

Other plant kappa hydroxylases are obtainable from the specific exemplified sequences provided 25 herein. Furthermore, it will be apparent that one can obtain natural and synthetic plant kappa hydroxylases including modified amino acid sequences and starting materials for synthetic-protein modeling from the exemplified plant kappa 30 hydroxylase and from plant kappa hydroxylases which are obtained through the use of such exemplified sequences. Modified amino acid sequences include sequences which have been mutated, truncated, elongated or the like, whether such sequences were

partially or wholly synthesized. Sequences which are actually purified from plant preparations or are identical or encode identical proteins thereto, regardless of the method used to obtain the protein 5 or sequence, are equally considered naturally derived.

Thus, one skilled in the art will readily recognize that antibody preparations, nucleic acid probes (DNA and RNA) or the like may be prepared and 10 used to screen and recover "homologous" or "related" kappa hydroxylases from a variety of plant sources. Typically, nucleic acid probes are labeled to allow detection, preferably with radioactivity although enzymes or other methods may also be used. For 15 immunological screening methods, antibody preparations either monoclonal or polyclonal are utilized. Polyclonal antibodies, although less specific, typically are more useful in gene isolation. For detection, the antibody is labeled 20 using radioactivity or any one of a variety of second antibody/enzyme conjugate systems that are commercially available.

Homologous sequences are found when there is an identity of sequence and may be determined upon 25 comparison of sequence information, nucleic acid or amino acid, or through hybridization reactions between a known kappa hydroxylase and a candidate source. Conservative changes, such as Glu/Asp, Val/Ile, Ser/Thr, Arg/Lys and Gln/Asn may also be 30 considered in determining sequence homology.

Typically, a lengthy nucleic acid sequence may show as little as 50-60% sequence identity, and more preferably at least about 70% sequence identity, between the target sequence and the given plant

kappa hydroxylase of interest excluding any deletions which may be present, and still be considered related. Amino acid sequences are considered homologous by as little as 25% sequence identity between the two complete mature proteins. (see generally, Doolittle, R.F., OF URFS and ORFS, University Science Books, CA, 1986.)

A genomic or other appropriate library prepared from the candidate plant source of interest may be probed with conserved sequences from the plant kappa hydroxylase to identify homologously related sequences. Use of an entire cDNA or other sequence may be employed if shorter probe sequences are not identified. Positive clones are then analyzed by restriction enzyme digestion and/or sequencing. When a genomic library is used, one or more sequences may be identified providing both the coding region, as well as the transcriptional regulatory elements of the kappa hydroxylase gene from such plant source. Probes can also be considerably shorter than the entire sequence. Oligonucleotides may be used, for example, but should be at least about 10, preferably at least about 15, more preferably at least 20 nucleotides in length. When shorter length regions are used for comparison, a higher degree of sequence identity is required than for longer sequences. Shorter probes are often particularly useful for polymerase chain reactions (PCR), especially when highly conserved sequences can be identified (see Gould et al., 1989 for examples of the use of PCR to isolate homologous genes from taxonomically diverse species).

When longer nucleic acid fragments are employed (>100 bp) as probes, especially when using

complete or large cDNA sequences, one would screen with low stringencies (for example, 40-50°C below the melting temperature of the probe) in order to obtain signal from the target sample with 20-50% deviation, i.e., homologous sequences (Beltz et al., 1983).

In a preferred embodiment, a plant kappa hydroxylase of this invention will have at least 60% overall amino acid sequence similarity with the exemplified plant kappa hydroxylase. In particular, kappa hydroxylases which are obtainable from an amino acid or nucleic acid sequence of a castor or *Lesquerella* kappa hydroxylase are especially preferred. The plant kappa hydroxylases may have preferential activity toward longer or shorter chain fatty acyl substrates. Plant fatty acyl hydroxylases having oleate-12-hydroxylase activity and eicosenoate-14-hydroxylase activity are both considered homologously related proteins because of *in vitro* evidence (Howling et al., 1972), and evidence disclosed herein, that the castor kappa hydroxylase will act on both substrates. Hydroxylated fatty acids may be subject to further enzymatic modification by other enzymes which are normally present or are introduced by genetic engineering methods. For example, 14-hydroxy-11,17-eicosadienoic acid, which is present in some *Lesquerella* species (Smith, 1985), is thought to be produced by desaturation of 14-hydroxy-11-eicosenoic acid.

Again, not only can gene clones and materials derived therefrom be used to identify homologous plant fatty acyl hydroxylases, but the resulting sequences obtained therefrom may also provide a

further method to obtain plant fatty acyl hydroxylases from other plant sources. In particular, PCR may be a useful technique to obtain related plant fatty acyl hydroxylases from sequence data provided herein. One skilled in the art will be able to design oligonucleotide probes based upon sequence comparisons or regions of typically highly conserved sequence. Of special interest are polymerase chain reaction primers based on the conserved regions of amino acid sequence between the castor kappa hydroxylase and the *L. fendleri* hydroxylase (SEQ ID NO:4). Details relating to the design and methods for a PCR reaction using these probes are described more fully in the examples.

It should also be noted that the fatty acyl hydroxylases of a variety of sources can be used to investigate fatty acid hydroxylation events in a wide variety of plant and *in vivo* applications. Because all plants synthesize fatty acids via a common metabolic pathway, the study and/or application of one plant fatty acid hydroxylase to a heterologous plant host may be readily achieved in a variety of species.

Once the nucleic acid sequence is obtained, the transcription, or transcription and translation (expression), of the plant fatty acyl hydroxylases in a host cell is desired to produce a ready source of the enzyme and/or modify the composition of fatty acids found therein in the form of free fatty acids, esters (particularly esterified to glycerolipids or as components of wax esters), estolides, or ethers. Other useful applications may be found when the host cell is a plant host cell, *in vitro* and *in vivo*. For example, by increasing the amount of an kappa

hydroxylase available to the plant, an increased percentage of ricinoleate or lesqueroleate (14-hydroxy-11-eicosenoic acid) may be provided.

Kappa Hydroxylase

5 By this invention, a mechanism for the biosynthesis of ricinoleic acid in plants is demonstrated. Namely, that a specific plant kappa hydroxylase having preferential activity toward fatty acyl substrates is involved in the
10 accumulation of hydroxylated fatty acids in at least some plant species. The use of the terms ricinoleate or ricinoleic acid (or lesqueroleate or lesquerolic acid, densipoleate etc.) is intended to include the free acids, the ACP and CoA esters, the salts of
15 these acids, the glycerolipid esters (particularly the triacylglycerol esters), the wax esters, the estolides and the ether derivatives of these acids.

The determination that plant fatty acyl hydroxylases are active in the *in vivo* production of
20 hydroxylated fatty acids suggests several possibilities for plant enzyme sources. In fact, hydroxylated fatty acids are found in some natural plant species in abundance. For example, three
25 hydroxy fatty acids related to ricinoleate occur in major amounts in seed oils from various *Lesquerella* species. Of particular interest, lesquerolic acid is a 20 carbon homolog of ricinoleate with two additional carbons at the carboxyl end of the chain (Smith, 1985). Other natural plant sources of
30 hydroxylated fatty acids include but are not limited to seeds of the *Linum* genus, seeds of *Wrightia* species, *Lycopodium* species, *Strophanthus* species,

Convolvulaceae species, *Calendula* species and many others (van de Loo et al., 1993).

Plants having significant presence of ricinoleate or lesqueroleate or desaturated other or 5 modified derivatives of these fatty acids are preferred candidates to obtain naturally-derived kappa hydroxylases. For example, *Lesquerella densipila* contains a diunsaturated 18 carbon fatty acid with a hydroxyl group (van de Loo et al., 1993) 10 that is thought to be produced by an enzyme that is closely related to the castor kappa hydroxylase, according to the theory on which this invention is based. In addition, a comparison between kappa hydroxylases and between plant fatty acyl 15 hydroxylases which introduce hydroxyl groups at positions other than the 12-carbon of oleate or the 14-carbon of lesqueroleate or on substrates other than oleic acid and icosenoic acid may yield insights for gene identification, protein modeling 20 or other modifications as discussed above.

Especially of interest are fatty acyl hydroxylases which demonstrate activity toward fatty acyl substrates other than oleate, or which introduce the hydroxyl group at a location other 25 than the C12 carbon. As described above, other plant sources may also provide sources for these enzymes through the use of protein purification, nucleic acid probes, antibody preparations, protein modeling, or sequence comparisons, for example, and 30 of special interest are the respective amino acid and nucleic acid sequences corresponding to such plant fatty acyl hydroxylases. Also, as previously described, once a nucleic acid sequence is obtained for the given plant hydroxylase, further plant

sequences may be compared and/or probed to obtain homologously related DNA sequences thereto and so on.

Genetic Engineering Applications

5 As is well known in the art, once a cDNA clone encoding a plant kappa hydroxylase is obtained, it may be used to obtain its corresponding genomic nucleic acid sequences thereto.

10 The nucleic acid sequences which encode plant kappa hydroxylases may be used in various constructs, for example, as probes to obtain further sequences from the same or other species.

15 Alternatively, these sequences may be used in conjunction with appropriate regulatory sequences to increase levels of the respective hydroxylase of interest in a host cell for the production of hydroxylated fatty acids or study of the enzyme *in vitro* or *in vivo* or to decrease or increase levels of the respective hydroxylase of interest for some 20 applications when the host cell is a plant entity, including plant cells, plant parts (including but not limited to seeds, cuttings or tissues) and plants.

25 A nucleic acid sequence encoding a plant kappa hydroxylase of this invention may include genomic, cDNA or mRNA sequence. By "encoding" is meant that the sequence corresponds to a particular amino acid sequence either in a sense or anti-sense orientation. By "recombinant" is meant that the 30 sequence contains a genetically engineered modification through manipulation via mutagenesis, restriction enzymes, or the like. A cDNA sequence may or may not encode pre-processing sequences, such

as transit or signal peptide sequences. Transit or signal peptide sequences facilitate the delivery of the protein to a given organelle and are frequently cleaved from the polypeptide upon entry into the 5 organelle, releasing the "mature" sequence. The use of the precursor DNA sequence is preferred in plant cell expression cassettes.

Furthermore, as discussed above the complete genomic sequence of the plant kappa hydroxylase may 10 be obtained by the screening of a genomic library with a probe, such as a cDNA probe, and isolating those sequences which regulate expression in seed tissue.

Once the desired plant kappa hydroxylase 15 nucleic acid sequence is obtained, it may be manipulated in a variety of ways. Where the sequence involves non-coding flanking regions, the flanking regions may be subjected to resection, mutagenesis, etc. Thus, transitions, transversions, deletions, 20 and insertions may be performed on the naturally occurring sequence. In addition, all or part of the sequence may be synthesized. In the structural gene, one or more codons may be modified to provide for a modified amino acid sequence, or one or more codon 25 mutations may be introduced to provide for a convenient restriction site or other purpose involved with construction or expression. The structural gene may be further modified by employing synthetic adapters, linkers to introduce one or more 30 convenient restriction sites, or the like.

The nucleic acid or amino acid sequences encoding a plant kappa hydroxylase of this invention may be combined with other non-native, or "heterologous", sequences in a variety of ways. By

"heterologous" sequences is meant any sequence which is not naturally found joined to the plant kappa hydroxylase, including, for example, combination of nucleic acid sequences from the same plant which are 5 not naturally found joined together.

The DNA sequence encoding a plant kappa hydroxylase of this invention may be employed in conjunction with all or part of the gene sequences normally associated with the kappa hydroxylase. In 10 its component parts, a DNA sequence encoding kappa hydroxylase is combined in a DNA construct having, in the 5' to 3' direction of transcription, a transcription initiation control region capable of promoting transcription and/or translation in a host 15 cell, the DNA sequence encoding plant kappa hydroxylase and a transcription and/or translation termination region.

Potential host cells include both prokaryotic and eukaryotic cells. A host cell may be unicellular 20 or found in a multicellular differentiated or undifferentiated organism depending upon the intended use. Cells of this invention may be distinguished by having a plant kappa hydroxylase foreign to the wild-type cell present therein, for 25 example, by having a recombinant nucleic acid construct encoding a plant kappa hydroxylase therein.

Depending upon the host, the regulatory regions will vary, including regions from viral, 30 plasmid or chromosomal genes, or the like. For expression in prokaryotic or eukaryotic microorganisms, particularly unicellular hosts, a wide variety of constitutive or regulatable promoters may be employed. Expression in a

microorganism can provide a ready source of the plant enzyme. Among transcriptional initiation regions which have been described are regions from bacterial and yeast hosts, such as *E. coli*, *B.*

5 *subtilis*, *Saccharomyces cerevisiae*, including genes such as beta-galactosidase, T7 polymerase, trpE or the like.

For the most part, the constructs will involve regulatory regions functional in plants which provide for modified production of plant kappa hydroxylase with resulting modification of the fatty acid composition. The open reading frame, coding for the plant kappa hydroxylase or functional fragment thereof will be joined at its 5' end to a transcription initiation regulatory region. Numerous transcription initiation regions are available which provide for a wide variety of constitutive or regulatable, e.g., inducible, transcription of the structural gene functions.

20 Among transcriptional initiation regions used for plants are such regions associated with the structural genes such as for nopaline and mannopine synthases, or with napin, soybean β -conglycinin, oleosin, 12S storage protein, the cauliflower mosaic virus 35S promoters or the like. The transcription/translation initiation regions corresponding to such structural genes are found immediately 5' upstream to the respective start codons.

In embodiments wherein the expression of the 30 kappa hydroxylase protein is desired in a plant host, the use of all or part of the complete plant kappa hydroxylase gene is desired. If a different promoter is desired, such as a promoter native to the plant host of interest or a modified promoter,

i.e., having transcription initiation regions derived from one gene source and translation initiation regions derived from a different gene source or enhanced promoters, such as double 35S
5 CaMV promoters, the sequences may be joined together using standard techniques.

For such applications when 5' upstream non-coding regions are obtained from other genes regulated during seed maturation, those

10 preferentially expressed in plant embryo tissue, such as transcription initiation control regions from the *B. napus* napin gene, or the *Arabidopsis* 12S storage protein, or soybean β -conglycinin (Bray et al., 1987) are desired. Transcription initiation
15 regions which are preferentially expressed in seed tissue, i.e., which are undetectable in other plant parts, are considered desirable for fatty acid modifications in order to minimize any disruptive or adverse effects of the gene product.

20 Regulatory transcript termination regions may be provided in DNA constructs of this invention as well. Transcript termination regions may be provided by the DNA sequence encoding the plant kappa hydroxylase or a convenient transcription

25 termination region derived from a different gene source, for example, the transcript termination region which is naturally associated with the transcript initiation region. Where the transcript termination region is from a different gene source,
30 it will contain at least about 0.5 kb, preferably about 1-3 kb of sequence 3' to the structural gene from which the termination region is derived.

Plant expression or transcription constructs having a plant kappa hydroxylase as the DNA sequence

of interest for increased or decreased expression thereof may be employed with a wide variety of plant life, particularly, plant life involved in the production of vegetable oils for edible and

5 industrial uses. Most especially preferred are temperate oilseed crops. Plants of interest include, but are not limited to rapeseed (canola and high erucic acid varieties), *Crambe*, *Brassica juncea*, *Brassica nigra*, meadowfoam, flax, sunflower,

10 safflower, cotton, *Cuphea*, soybean, peanut, coconut and oil palms and corn. An important criterion in the selection of suitable plants for the introduction on the kappa hydroxylase is the presence in the host plant of a suitable substrate

15 for the hydroxylase. Thus, for example, production of ricinoleic acid will be best accomplished in plants that normally have high levels of oleic acid in seed lipids. Similarly, production of lesquerolic acid will best be accomplished in plants that have

20 high levels of icosenoic acid in seed lipids.

Depending on the method for introducing the recombinant constructs into the host cell, other DNA sequences may be required. Importantly, this invention is applicable to dicotyledons and

25 monocotyledons species alike and will be readily applicable to new and/or improved transformation and regulation techniques. The method of transformation is not critical to the current invention; various methods of plant transformation are currently

30 available. As newer methods are available to transform crops, they may be directly applied hereunder. For example, many plant species naturally susceptible to *Agrobacterium* infection may be successfully transformed via tripartite or binary

vector methods of *Agrobacterium* mediated transformation. In addition, techniques of microinjection, DNA particle bombardment, electroporation have been developed which allow for 5 the transformation of various monocot and dicot plant species.

In developing the DNA construct, the various components of the construct or fragments thereof will normally be inserted into a convenient cloning 10 vector which is capable of replication in a bacterial host, e.g., *E. coli*. Numerous vectors exist that have been described in the literature. After each cloning, the plasmid may be isolated and subjected to further manipulation, such as 15 restriction, insertion of new fragments, ligation, deletion, insertion, resection, etc., so as to tailor the components of the desired sequence. Once the construct has been completed, it may then be transferred to an appropriate vector for further 20 manipulation in accordance with the manner of transformation of the host cell.

Normally, included with the DNA construct will be a structural gene having the necessary regulatory regions for expression in a host and 25 providing for selection of transformant cells. The gene may provide for resistance to a cytotoxic agent, e.g., antibiotic, heavy metal, toxin, etc., complementation providing prototropy to an auxotrophic host, viral immunity or the like. 30 Depending upon the number of different host species the expression construct or components thereof are introduced, one or more markers may be employed, where different conditions for selection are used for the different hosts.

It is noted that the degeneracy of the DNA code provides that some codon substitutions are permissible of DNA sequences without any corresponding modification of the amino acid sequence.

5

</div

In some instances where *Agrobacterium* is used as the vehicle for transforming plant cells, the expression construct bordered by the T-DNA border(s) will be inserted into a broad host spectrum vector, 5 there being broad host spectrum vectors described in the literature. Commonly used is pRK2 or derivatives thereof. See, for example, Ditta et al. (1980), which is incorporated herein by reference. Included with the expression construct and the T-DNA will be 10 one or more markers, which allow for selection of transformed *Agrobacterium* and transformed plant cells. A number of markers have been developed for use with plant cells, such as resistance to kanamycin, the aminoglycoside G418, hygromycin, or 15 the like. The particular marker employed is not essential to this invention, one or another marker being preferred depending on the particular host and the manner of construction.

For transformation of plant cells using 20 *Agrobacterium*, explants may be combined and incubated with the transformed *Agrobacterium* for sufficient time for transformation, the bacteria killed, and the plant cells cultured in an appropriate selective medium. Once callus forms, 25 shoot formation can be encouraged by employing the appropriate plant hormones in accordance with known methods and the shoots transferred to rooting medium for regeneration of plants. The plants may then be grown to seed and the seed used to establish 30 repetitive generations and for isolation of vegetable oils.

Using Hydroxylase Genes to Alter the Activity of Fatty Acid Desaturases

A widely acknowledged goal of current efforts to improve the nutritional quality of edible plant oils, or to facilitate industrial applications of plant oils, is to alter the level of desaturation of plant storage lipids (Topfer et al., 1995). In particular, in many crop species it is considered desirable to reduce the level of polyunsaturation of storage lipids and to increase the level of oleic acid. The precise amount of the various fatty acids in a particular plant oil varies with the intended application. Thus, it is desirable to have a robust method that will permit genetic manipulation of the level of unsaturation to any desired level.

Substantial progress has recently been made in the isolation of genes encoding plant fatty acid desaturases (reviewed in Topfer et al., 1995). These genes have been introduced into various plant species and used to alter the level of fatty acid unsaturation in one of three ways. First, the genes can be placed under transcriptional control of a strong promoter so that the amount of the corresponding enzyme is increased. In some cases this leads to an increase in the amount of the fatty acid that is the product of the reaction catalyzed by the enzyme. For example, Arondel et al. (1992) increased the amount of linolenic acid (18:3) in tissues of transgenic *Arabidopsis* plants by placing the endoplasmic reticulum-localized fad3 gene under transcriptional control of the strong constitutive cauliflower mosaic virus 35S promoter.

A second method of using cloned genes to alter the level of fatty acid unsaturation is to

cause transcription of all or part of a gene in transgenic tissues so that the transcripts have an antisense orientation relative to the normal mode of transcription. This has been used by a number of 5 laboratories to reduce the level of expression of one or more desaturase genes that have significant nucleotide sequence homology to the gene used in the construction of the antisense gene (reviewed in Topfer et al.). For instance, antisense repression 10 of the oleate Δ 12-desaturase in transgenic rapeseed resulted in a strong increase in oleic acid content (cf., Topfer et al., 1995).

A third method for using cloned genes to alter fatty acid desaturation is to exploit the 15 phenomenon of cosuppression or "gene-silencing" (Matzke et al., 1995). Although the mechanisms responsible for gene silencing are not known in any detail, it has frequently been observed that in transgenic plants, expression of an introduced gene 20 leads to inactivation of homologous endogenous genes.

For example, high-level sense expression of the *Arabidopsis fad8* gene, which encodes a chloroplast-localized Δ 15-desaturase, in transgenic 25 *Arabidopsis* plants caused suppression of the endogenous copy of the *fad8* gene and the homologous *fad7* gene (which encodes an isozyme of the *fad8* gene) (Gibson et al., 1994). The *fad7* and *fad8* genes are only 76% identical at the nucleotide level. At 30 the time of publication, this example represented the most divergent pair of plant genes for which cosuppression had been observed.

In view of previous evidence concerning the relatively high level of nucleotide sequence

homology required to obtain cosuppression, it is not obvious to one skilled in the art that sense expression in transgenic plants of the castor fatty acyl hydroxylase of this invention would 5 significantly alter the amount of unsaturation of storage lipids.

However, the present inventors establish that fatty acyl hydroxylase genes can be used for this purpose as taught in Example 4 of this specification. Of particular importance, this invention teaches the use of fatty acyl hydroxylase genes to increase the proportion of oleic acid in transgenic plant tissues. The mechanism by which expression of the gene exerts this effect is not 15 known but may be due to one of several possibilities which are elaborated upon in Example 4.

The invention now being generally described, it will be more readily understood by reference to the following examples which are included for 20 purposes of illustration only and are not intended to limit the present invention.

EXAMPLES

In the experimental disclosure which follows, all temperatures are given in degrees centigrade 25 ($^{\circ}\text{C}$), weights are given in grams (g), milligram (mg) or micrograms (μg), concentrations are given as molar (M), millimolar (mM) or micromolar (μM) and all volumes are given in liters (l), microliters (µl) or milliliters (ml), unless otherwise 30 indicated.

EXAMPLE 1 - PRODUCTION OF NOVEL HYDROXYLATED FATTY ACIDS IN ARABIDOPSIS THALIANA

Overview

The kappa hydroxylase encoded by the fah12 gene from castor was used to produce ricinoleic acid, lesquerolic acid, densipolic acid and auricolic acid in transgenic *Arabidopsis* plants.

Production of transgenic plants

A variety of methods have been developed to insert a DNA sequence of interest into the genome of a plant host to obtain the transcription and translation of the sequence to effect phenotypic changes. The following methods represent only one of many equivalent means of producing transgenic plants and causing expression of the hydroxylase gene.

Arabidopsis plants were transformed, by *Agrobacterium*-mediated transformation, with the kappa hydroxylase encoded by the castor fah12 gene on binary Ti plasmid pB6. This plasmid has also been used to transform *Nicotiana tabacum* for the production of ricinoleic acid.

Inoculums of *Agrobacterium tumefaciens* strain GV3101 containing binary Ti plasmid pB6 were plated on L-broth plates containing 50 µg/ml kanamycin and incubated for 2 days at 30°C. Single colonies were used to inoculate large liquid cultures (L-broth medium with 50 mg/l rifampicin, 110 mg/l gentamycin and 200 mg/l kanamycin) to be used for the transformation of *Arabidopsis* plants.

Arabidopsis plants were transformed by the *in planta* transformation procedure essentially as described by Bechtold et al. (1993). Cells of *A. tumefaciens* GV3101(pB6) were harvested from liquid

cultures by centrifugation, then resuspended in infiltration medium at $OD_{600} = 0.8$. Infiltration medium was Murashige and Skoog macro and micronutrient medium (Sigma Chemical Co., St. Louis, MO) containing 10 mg/l 6-benzylaminopurine and 5% glucose. Batches of 12-15 plants were grown for 3 to 4 weeks in natural light at a mean daily temperature of approximately 25°C in 3.5 inch pots containing soil. The intact plants were immersed in the bacterial suspension then transferred to a vacuum chamber and placed under 600 mm of vacuum produced by a laboratory vacuum pump until tissues appeared uniformly water-soaked (approximately 10 min). The plants were grown at 25°C under continuous light (100 $\mu\text{mol m}^{-2} \text{ s}^{-1}$ irradiation in the 400 to 700 nm range) for four weeks. The seeds obtained from all the plants in a pot were harvested as one batch. The seeds were sterilized by sequential treatment for 2 min with ethanol followed by 10 min in a mixture of household bleach (Chlorox), water and Tween-80 (50%, 50%, 0.05%) then rinsed thoroughly with sterile water. The seeds were plated at high density (2000 to 4000 per plate) onto agar-solidified medium in 100 mm petri plates containing 1/2 X Murashige and Skoog salts medium enriched with B5 vitamins (Sigma Chemical Co., St. Louis, MO) and containing kanamycin at 50 mg/l. After incubation for 48 h at 4°C to stimulate germination, seedlings were grown for a period of seven days until transformants were clearly identifiable as healthy green seedlings against a background of chlorotic kanamycin-sensitive seedlings. The transformants were transferred to soil for two weeks before leaf tissue

could be used for DNA and lipid analysis. More than 20 transformants were obtained.

DNA was extracted from young leaves from transformants to verify the presence of an intact fah12 gene. The presence of the transgene in a number of the putative transgenic lines was verified by using the polymerase chain reaction to amplify the insert from pB6. The primers used were HF2 = GCTCTTTGTGCCTCATTC (SEQ ID NO:12) and HR1 = CGGTACCAAGAAAAGCCTTG (SEQ ID NO:13), which were designed to allow the amplification of a 700 bp fragment. Approximately 100 ng of genomic DNA was added to a solution containing 25 pmol of each primer, 1.5 U Taq polymerase (Boehringer Manheim), 200 uM of dNTPs, 50 mM KCl, 10 mM Tris.Cl (pH 9), 0.1% (v/v) Triton X-100, 1.5 mM MgCl₂, 3% (v/v) formamide, to a final volume of 50 µl. Amplifications conditions were: 4 min denaturation step at 94°C, followed by 30 cycles of 92°C for 1 min, 55°C for 1 min, 72°C for 2 min. A final extension step closed the program at 72°C for 5 min. Transformants could be positively identified after visualization of a characteristic 1 kb amplified fragment on an ethidium bromide stained agarose gel. All transgenic lines tested gave a PCR product of a size consistent with the expected genotype, confirming that the lines were, indeed, transgenic. All further experiments were done with three representative transgenic lines of the wild type designated as 1-3, 4D, 7-4 and one transgenic line of the fad2 mutant line JB12. The transgenic JB12 line was included in order to test whether the increased accumulation of oleic acid in this mutant

would have an effect on the amount of ricinoleic acid that accumulated in the transgenic plants.

Analysis of transgenic plants

Leaves and seeds from fah12 transgenic 5 *Arabidopsis* plants were analyzed for the presence of hydroxylated fatty acids using gas chromatography. Lipids were extracted from 100-200 mg leaf tissue or 50 seeds. Fatty acid methyl esters (FAMES) were prepared by placing tissue in 1.5 ml of 1.0 M 10 methanolic HCl (Supelco Co.) in a 13 x 100 mm glass screw-cap tube capped with a teflon-lined cap and heated to 80°C for 2 hours. Upon cooling, 1 ml petroleum ether was added and the FAMES removed by aspirating off the ether phase which was then dried 15 under a nitrogen stream in a glass tube. One hundred μ l of N,O-bis(Trimethylsilyl) trifluoroacetamide (BSTFA; Pierce Chemical Co) and 200 μ l acetonitrile was added to derivatize the hydroxyl groups. The reaction was carried out at 70°C for 15 min. The 20 products were dried under nitrogen, redissolved in 100 μ l chloroform and transferred to a gas chromatograph vial. Two μ l of each sample were analyzed on a SP2340 fused silica capillary column (30 m, 0.75 mm ID, 0.20 mm film, Supelco), using a 25 Hewlett-Packard 5890 II series Gas Chromatograph. The samples were not split, the temperature program was 195°C for 18 min, increased to 230°C at 25°C/min., held at 230°C for 5 min then down to 195°C at 25°C/min., and flame ionization detectors were 30 used.

The chromatographic elution time of methyl esters and O-TMS derivatives of ricinoleic acid, lesquerolic acid and euricolic acid was established

by GC-MS of lipid samples from seeds of *L. fendleri* and comparison to published chromatograms of fatty acids from this species (Carlson et al., 1990). A O-TMS-methyl-ricinoleate standard was prepared from 5 ricinoleic acid obtained from Sigma Chemical Co (St, Louis, MO). O-TMS-methyl-lesqueroleate and O-TMS-methyl-auricoleate standards were prepared from triacylglycerols purified from seeds of *L. fendleri*. The mass spectrum of O-TMS-methyl-ricinoleate, O-TMS-methyl-densipoleate, O-TMS-methyl-lesqueroleate, 10 and O-TMS-methyl-auricoleate are shown in Figures 1A-D, respectively. The structures of the characteristic ions produced during mass spectrometry of these derivatives are shown in 15 Figure 2.

Lipid extracted from transgenic tissues were analyzed by gas chromatography and mass spectrometry for the presence of hydroxylated fatty acids. As a matter of reference, the average fatty acid 20 composition of leaves in *Arabidopsis* wild type and *fad2* mutant lines was reported by Miquel and Browse (1992). Gas chromatograms of methylated and silylated fatty acids from seeds of wild type and a *fah12* transgenic wild type plant are shown in 25 Figures 3A and 3B, respectively. The profiles are very similar except for the presence of three small but distinct peaks at 14.3, 15.9 and 18.9 minutes. A very small peak at 20.15 min was also evident. The elution time of the peaks at 14.3 and 18.9 min 30 corresponded precisely to that of comparably prepared ricinoleic and lesquerolic standards, respectively. No significant differences were observed in lipid extracts from leaves or roots of

the wild type and the fah12 transgenic wild type lines (Table 1).

Thus, in spite of the fact that the fah12 gene is expressed throughout the plant, effects on fatty acid composition was observed only in seed tissue. The present inventors have made a similar observation for transgenic fah12 tobacco.

Table 1. Fatty acid composition of lipids from transgenic and wild type *Arabidopsis*. The values are the means obtained from analysis of samples from three independent transgenic lines, or three independent samples of wild type and fad2 lines.

TABLE 1

Fatty acid	Seed				Leaf			Root	
	WT	<u>FAH12</u>	<u>FAH12</u>	JB12	WT	<u>FAH12</u>	WT	<u>FAH12</u>	WT
16:0	8.5	8.2	6.4	6.1	16.5	17.5	23.9	24.9	
16:3	0	0	0	0	10.1	9.8	0	0	
18:0	3.2	3.5	2.9	3.5	1.3	1.2	2.0	1.9	
18:1	15.4	26.3	43.4	47.8	2.4	3.4	5.4	3.2	
18:2	27.0	21.4	10.2	7.2	15.1	14.0	32.2	29.4	
18:3	22.0	16.6	-	9.7	36.7	36.0	26.7	30.6	
20:1	14.0	14.3	-	13.1	0	0	0	0	

TABLE 1 (continued)

Fatty acid	Seed				Leaf			Root		
	WT	<u>FAH12</u>	<u>FAH12</u>	JB12	WT	<u>FAH12</u>	WT	WT	<u>FAH12</u>	WT
18:1-OH	0	0.4	0.3	0	0	0	0	0	0	0
18:2-OH	0	0.4	0.3	0	0	0	0	0	0	0
20:1-OH	0	0.2	0.1	0	0	0	0	0	0	0
20:2-OH	0	0.1	0.1	0	0	0	0	0	0	0

In order to confirm that the observed new peaks in the transgenic lines corresponded to derivatives of ricinoleic, lesquerolic, densipolic and auricolic acids, mass spectrometry was used. The fatty acid derivatives were resolved by gas chromatography as described above except that a Hewlett-Packard 5971 series mass selective detector was used in place of the flame ionization detector used in the previous experiment. The spectra of the four new peaks in Figure 3B (peak numbers 10, 11, 12 and 13) are shown in Figures 4A-D, respectively. Comparison of the spectrum obtained for the standards with that obtained for the four peaks from the transgenic lines confirms the identity of the four new peaks. On the basis of the three characteristic peaks at M/Z 187, 270 and 299, peak 10 is unambiguously identified as O-TMS-methylricinoleate. On the basis of the three characteristic peaks at M/Z 185, 270 and 299, peak 11 is unambiguously identified as O-TMS-methyldensipoleate. On the basis of the three characteristic peaks at M/Z 187, 298 and 327, peak 12 is unambiguously identified as O-TMS-methyllesqueroleate. On the basis of the three characteristic peaks at M/Z 185, 298 and 327, peak 13 is unambiguously identified as O-TMS-methylauricoleate.

These results unequivocally demonstrate the identity of the fah12 cDNA as encoding a hydroxylase that hydroxylates both oleic acid to produce ricinoleic acid and also hydroxylates icosenoic acid to produce lesquerolic acid. These results also provide additional evidence that the hydroxylase can be functionally expressed in a heterologous plant

species in such a way that the enzyme is catalytically functional. These results also demonstrate that expression of this hydroxylase gene leads to accumulation of ricinoleic, lesquerolic, 5 densipolic and auricolic acids in a plant species that does not normally accumulate hydroxylated fatty acids in extractable lipids.

The present inventors expected to find lesquerolic acid in the transgenic plants based on 10 the biochemical evidence suggesting broad substrate specificity of the kappa hydroxylase. By contrast, the accumulation of densipolic and auricolic acids was less predictable. Since *Arabidopsis* does not normally contain significant quantities of the non- 15 hydroxylated precursors of these fatty acids which could serve as substrates for the hydroxylase, it appears that one or more of the three n-3 fatty acid desaturases known in *Arabidopsis* (e.g., fad3, fad7, fad8; reviewed in Gibson et al., 1995) are capable 20 of desaturating the hydroxylated compounds at the n-3 position. That is, densipolic acid is produced by the action of an n-3 desaturase on ricinoleic acid. Auricolic acid is produced by the action of an n-3 desaturase on lesquerolic acid. Because it is 25 located in the endoplasmic reticulum, the fad3 desaturase is almost certainly responsible. This can be tested in the future by producing fah12-containing transgenic plants of the fad3-deficient mutant of *Arabidopsis* (similar experiments can be 30 done with fad7 and fad8). It is also formally possible that the enzymes that normally elongate 18:1^{cisΔ9} to 20:1^{cisΔ11} may elongate 12OH-18:1^{cisΔ9} to 18:1^{cisΔ9} to 20:1^{cisΔ11}, and 12OH-18:2^{cisΔ9,15} to 14OH-20:2^{cisΔ11,17}.

The amount of the various fatty acids in seed, leaf and root lipids of the control and transgenic plants is also presented in Table 1. Although the amount of hydroxylated fatty acids produced in this example is less than desired for production of ricinoleate and other hydroxylated fatty acids from plants, numerous improvements may be envisioned that will increase the level of accumulation of hydroxylated fatty acids in plants that express the fah12 or related hydroxylase genes. Improvements in the level and tissue specificity of expression of the hydroxylase gene are envisioned. Methods to accomplish this by the use of strong, seed-specific promoters such as the *B. napus* napin promoter will be obvious to one skilled in the art. Additional improvements are envisioned that involve modification of the enzymes which cleave hydroxylated fatty acids from phosphatidylcholine, reduction in the activities of enzymes which degrade hydroxylated fatty acids and replacement of acyltransferases which transfer hydroxylated fatty acids to the sn-1, sn-2 and sn-3 positions of glycerolipids. Although genes for these enzymes have not been described in the scientific literature, their utility in improving the level of production of hydroxylated fatty acids can be readily appreciated based on the results of biochemical investigations of ricinoleate synthesis.

Although *Arabidopsis* is not an economically important plant species, it is widely accepted by plant biologists as a model for higher plants. Therefore, the inclusion of this example is intended to demonstrate the general utility of the invention described here to the modification of oil

composition in higher plants. One advantage of studying the expression of this novel gene in *Arabidopsis* is the existence in this system of a large body of knowledge on lipid metabolism, as well as the availability of a collection of mutants which can be used to provide useful information on the biochemistry of fatty acid hydroxylation in plant species. Another advantage is the ease of transposing any of the information obtained on metabolism of ricinoleate in *Arabidopsis* to closely related species such as the crop plants *Brassica napus*, *Brassica juncea* or *Crambe abyssinica* in order to mass produce ricinoleate, lesqueroleate or other hydroxylated fatty acids for industrial use. The kappa hydroxylase is useful for the production of ricinoleate or lesqueroleate in any plant species that accumulates significant levels of the precursors, oleic acid and icosenoic acid. Of particular interest are genetically modified varieties that accumulate high levels of oleic acid. Such varieties are currently available for sunflower and canola. Production of lesquerolic acid and related hydroxy fatty acids can be achieved in species that accumulate high levels of icosenoic acid or other long chain monoenoic acids. Such plants may in the future be produced by genetic engineering of plants that do not normally make such precursors. Thus, the use of the kappa hydroxylase will be of general utility.

EXAMPLE 2. ISOLATION OF LESQUERELLA KAPPA
HYDROXYLASE GENOMIC CLONE

Overview

Regions of nucleotide sequence that were
5 conserved in both the castor kappa hydroxylase and
the *Arabidopsis fad2* $\Delta 12$ fatty acid desaturase were
used to design oligonucleotide primers. These were
used with genomic DNA from *Lesquerella fendleri* to
amplify fragments of several homologous genes. These
10 amplified fragments were then used as hybridization
probes to identify full length genomic clones from a
genomic library of *L. fendleri*.

Hydroxylated fatty acids are specific to the
seed tissue of *Lesquerella* sp., and are not found to
15 any appreciable extent in vegetative tissues. One of
the two genes identified by this method was
expressed in both leaves and developing seeds and is
therefore thought to correspond to the $\Delta 12$ fatty
acid desaturase. The other gene was expressed at
20 high levels in developing seeds but was not
expressed or was expressed at very low levels in
leaves and is the kappa hydroxylase from this
species. The identity of the gene as a fatty acyl
hydroxylase was established by functional expression
25 of the gene in yeast.

The identity of this gene will also be
established by introducing the gene into transgenic
Arabidopsis plants and showing that it causes the
accumulation of ricinoleic acid, lesquerolic acid,
30 densipolic acid and auricolic acid in seed lipids.

The various steps involved in this process
are described in detail below. Unless otherwise
indicated, routine methods for manipulating nucleic

acids, bacteria and phage were as described by Sambrook et al. (1989).

Isolation of a fragment of the *Lesquerella kappa* hydroxylase gene

5 Oligonucleotide primers for the amplification of the *L. fendleri* kappa hydroxylase were designed by choosing regions of high deduced amino acid sequence homology between the castor kappa hydroxylase and the *Arabidopsis* Δ 12 desaturase (fad2). Because most amino acids are encoded by several different codons, these oligonucleotides were designed to encode all possible codons that could encode the corresponding amino acids.

10 The sequence of these mixed oligonucleotides was Oligo 1: TAYWSNCAYMGNMGNCAYCA (SEQ ID NO:14) and Oligo 2: RTGRTGNGCNACRTGNGTRTC (SEQ ID NO:15) where Y = C+T, W = A+T, S = G+C, N = A+G+C+T, M = A+C, and R = A+G.

15 These oligonucleotides were used to amplify a fragment of DNA from *L. fendleri* genomic DNA by the polymerase chain reaction (PCR) using the following conditions: Approximately 100 ng of genomic DNA was added to a solution containing 25 pmol of each primer, 1.5 U Taq polymerase (Boehringer Manheim), 200 uM of dNTPs, 50 mM KCl, 10 mM Tris.Cl (pH 9), 0.1% (v/v) Triton X-100, 1.5 mM MgCl₂, 3% (v/v) formamide, to a final volume of 50 μ l.

25 Amplifications conditions were: 4 min denaturation step at 94°C, followed by 30 cycles of 92°C for 1 min, 55°C for 1 min, 72°C for 2 min. A final extension step closed the program at 72°C for 5 min.

30 PCR products of approximately 540 bp were observed following electrophoretic separation of the

products of the PCR reaction in agarose gels. Two of these fragments were cloned into pBluescript (Stratagene) to give rise to plasmids pLesq2 and pLesq3. The sequence of the inserts in these two 5 plasmids was determined by the chain termination method. The sequence of the insert in pLesq2 is presented as Figure 5 (SEQ ID NO:1) and the sequence of the insert in pLesq3 is presented as Figure 6 (SEQ ID NO:2). The high degree of sequence identity 10 between the two clones indicated that they were both potential candidates to be either a $\Delta 12$ desaturase or a kappa hydroxylase.

Northern analysis

In *L. fendleri*, hydroxylated fatty acids are 15 found in large amounts in seed oils but are not found in appreciable amounts in leaves. An important criterion in discriminating between a fatty acyl desaturase and kappa hydroxylase is that the kappa hydroxylase gene is expected to be expressed more 20 highly in tissues which have high level of hydroxylated fatty acids than in other tissues. In contrast, all plant tissues should contain mRNA for an $\omega 6$ fatty acyl desaturase since diunsaturated fatty acids are found in the lipids of all tissues 25 in most or all plants.

Therefore, it was of great interest to determine whether the gene corresponding to pLesq2 was also expressed only in seeds, or is also expressed in other tissues. This question was 30 addressed by testing for hybridization of pLesq2 to RNA purified from developing seeds and from leaves.

Total RNA was purified from developing seeds and young leaves of *L. fendleri* using an Rneasy RNA

extraction kit (Qiagen), according to the manufacturer's instructions. RNA concentrations were quantified by UV spectrophotometry at $\lambda=260$ and 280 nm. In order to ensure even loading of the gel to be used for Northern blotting, RNA concentrations were further adjusted after recording fluorescence under UV light of RNA samples stained with ethidium bromide and run on a test denaturing gel.

Total RNA prepared as described above from leaves and developing seeds was electrophoresed through an agarose gel containing formaldehyde (Iba et al., 1993). An equal quantity (10 μ g) of RNA was loaded in both lanes, and RNA standards (0.16-1.77 kb ladder, Gibco-BRL) were loaded in a third lane. Following electrophoresis, RNA was transferred from the gel to a nylon membrane (Hybond N+, Amersham) and fixed to the filter by exposure to UV light.

A 32 P-labelled probe was prepared from insert DNA of clone pLesq2 by random priming and hybridized to the membrane overnight at 52°C, after it had been prehybridized for 2 h. The prehybridization solution contained 5X SSC, 10X Denhardt's solution, 0.1% SDS, 0.1M KPO₄, pH 6.8, 100 μ g/ml salmon sperm DNA. The hybridization solution had the same basic composition, but no SDS, and it contained 10% dextran sulfate and 30% formamide. The blot was washed once in 2X SSC, 0.5% SDS at 65°C then in 1X SSC at the same temperature.

Brief (30 min) exposure of the blot to X-ray film revealed that the probe pLesq2 hybridized to a single band only in the seed RNA lane (Figure 7). The blot was re-probed with the insert from pLesq3 gene, which gave bands of similar intensity in the seed and leaf lanes (Figure 7).

These results show that the gene corresponding to the clone pLesq2 is highly and specifically expressed in seed of *L. fendleri*. In conjunction with knowledge of the nucleotide and deduced amino acid sequence, strong seed-specific expression of the gene corresponding to the insert in pLesq2 is a convincing indicator of the role of the enzyme in synthesis of hydroxylated fatty acids in the seed oil.

10 Characterization of a genomic clone of the kappa hydroxylase

Genomic DNA was prepared from young leaves of *L. fendleri* as described by Murray and Thompson (1980). A Sau3AI-partial digest genomic library 15 constructed in the vector λDashII (Stratagene, 11011 North Torrey Pines Road, La Jolla CA 92037) was prepared by partially digesting 500 µg of DNA, size-selecting the DNA on a sucrose gradient (Sambrook et al., 1989), and ligating the DNA (12 kb average 20 size) to the *Bam*HI-digested arms of λDashII. The entire ligation was packaged according to the manufacturer's conditions and plated on *E. coli* strain XL1-Blue MRA-P2 (Stratagene). This yielded 5x10⁵ primary recombinant clones. The library was 25 then amplified according to the manufacturer's conditions. A fraction of the genomic library was plated on *E. coli* XL1-Blue and resulting plaques (150,000) were lifted to charged nylon membranes (Hybond N+, Amersham), according to the manufacturer's conditions. DNA was crosslinked to 30 the filters under UV in a Stratalinker (Stratagene).

Several clones carrying genomic sequences corresponding to the *L. fendleri* hydroxylase were

isolated by probing the membranes with the insert from pLesq2 that was PCR-amplified with internal primers and labelled with ^{32}P by random priming. The filters were prehybridized for 2 hours at 65°C in 7% SDS, 1mM EDTA, 0.25 M Na₂HPO₄ (pH 7.2), 1% BSA and hybridized to the probe for 16 hours in the same solution. The filters were sequentially washed at 65°C in solutions containing 2 X SSC, 1 X SSC, 0.5 X SSC in addition to 0.1 % SDS. A 2.6 kb *Xba*I fragment containing the complete coding sequence for the kappa hydroxylase and approximately 1 kb of the 5' upstream region was subcloned into the corresponding site of pBluescript KS to produce plasmid pLesq-Hyd and the sequence determined completely using an automatic sequencer by the dideoxy chain termination method. Sequence data was analyzed using the program DNASIS (Hitachi Company).

The sequence of the insert in clone pLesq-Hyd is shown in Figures 8A-B. The sequence entails 1855 bp of contiguous DNA sequence (SEQ ID NO:3). The clone encodes a 401 bp 5' untranslated region (i.e., nucleotides preceding the first ATG codon), an 1152 bp open reading frame, and a 302 bp 3' untranslated region. The open reading frame encodes a 384 amino acid protein with a predicted molecular weight of 44,370 (SEQ ID NO:4). The amino terminus lacks features of a typical signal peptide (von Heijne, 1985).

The exact translation-initiation methionine has not been experimentally determined, but on the basis of deduced amino acid sequence homology to the castor kappa hydroxylase (noted below) is thought to be the methionine encoded by the first ATG codon at nucleotide 402.

Comparison of the pLesq-Hyd deduced amino acid sequence with sequences of membrane-bound desaturases and the castor hydroxylase (Figures 9A-B) indicates that pLesq-Hyd is homologous to these genes. This figure shows an alignment of the *L. fendleri* hydroxylase (SEQ ID NO:4) with the castor hydroxylase (van de Loo et al., 1995), the *Arabidopsis fad2* cDNA which encodes an endoplasmic reticulum-localized Δ12 desaturase (called fad2) (Okuley et al., 1994), two soybean fad2 desaturase clones, a *Brassica napus* fad2 clone, a *Zea mays* fad2 clone and partial sequence of a *R. communis* fad2 clone.

The high degree of sequence homology indicates that the gene products are of similar function. For instance, the overall homology between the *Lesquerella* hydroxylase and the *Arabidopsis fad2* desaturase was 92.2% similarity and 84.8% identity and the two sequences differed in length by only one amino acid.

Southern hybridization

Southern analysis was used to examine the copy number of the genes in the *L. fendleri* genome corresponding to the clone pLesq-Hyd. Genomic DNA (5 μg) was digested with EcoRI, HindIII and XbaI and separated on a 0.9% agarose gel. DNA was alkali-blotted to a charged nylon membrane (Hybond N+, Amersham), according to the manufacturer's protocol. The blot was prehybridized for 2 hours at 65°C in 7% SDS, 1mM EDTA, 0.25 M Na₂HPO₄ (pH 7.2), 1% BSA and hybridized to the probe for 16 hours in the same solution with pLesq-Hyd insert PCR-amplified with internal primers and labelled with ³²P by random

priming. The filters were sequentially washed at 65°C in solutions containing 2 X SSC, 1 X SSC, 0.5 X SSC in addition to 0.1 % SDS, then exposed to X-ray film.

5 The probe hybridized with a single band in each digest of *L. fendleri* DNA (Figure 10), indicating that the gene from which pLesq-Hyd was transcribed is present in a single copy in the *L. fendleri* genome.

10 Expression of pLesq-Hyd in Transgenic Plants

There are a wide variety of plant promoter sequences which may be used to cause tissue-specific expression of cloned genes in transgenic plants. For instance, the napin promoter and the acyl carrier protein promoters have previously been used in the modification of seed oil composition by expression of an antisense form of a desaturase (Knutson et al., 1992). Similarly, the promoter for the β -subunit of soybean β -conglycinin has been shown to be highly active and to result in tissue-specific expression in transgenic plants of species other than soybean (Bray et al., 1987). Thus, other promoters which lead to seed-specific expression may also be employed for the production of modified seed oil composition. Such modifications of the invention described here will be obvious to one skilled in the art.

Constructs for expression of *L. fendleri* kappa hydroxylase in plant cells are prepared as follows: A 13 kb SalI fragment containing the pLesq-Hyg gene was ligated into the XhoI site of binary Ti plasmid vector pSLJ44026 (Jones et al., 1992) (Figure 11) to produce plasmid pTi-Hyd and

transformed into *Agrobacterium tumefaciens* strains GV3101 by electroporation. Strain GV3101 (Koncz and Schell, 1986) contains a disarmed Ti plasmid. Cells for electroporation were prepared as follows. GV3101
5 was grown in LB medium with reduced NaCl (5 g/l). A 250 ml culture was grown to OD₆₀₀ = 0.6, then centrifuged at 4000 rpm (Sorvall GS-A rotor) for 15 min. The supernatant was aspirated immediately from the loose pellet, which was gently resuspended in
10 500 ml ice-cold water. The cells were centrifuged as before, resuspended in 30 ml ice-cold water, transferred to a 30 ml tube and centrifuged at 5000 rpm (Sorvall SS-34 rotor) for 5 min. This was repeated three times, resuspending the cells
15 consecutively in 30 ml ice-cold water, 30 ml ice-cold 10% glycerol, and finally in 0.75 ml ice-cold 10% glycerol. These cells were aliquoted, frozen in liquid nitrogen, and stored at -80°C.

Electroporations employed a Biorad Gene Pulser instrument using cold 2 mm-gap cuvettes containing 40 µl cells and 1 µl of DNA in water, at a voltage of 2.5 KV, and 200 Ohms resistance. The electroporated cells were diluted with 1 ml SOC medium (Sambrook et al., 1989, page A2) and
25 incubated at 28°C for 2-4 h before plating on medium containing kanamycin (50 mg/l).

Arabidopsis thaliana can be transformed with the *Agrobacterium* cells containing pTi-Hyd as described in Example 1 above. Similarly, the presence of hydroxylated fatty acids in the transgenic *Arabidopsis* plants can be demonstrated by the methods described in Example 1 above.
30

Constitutive expression of the *L. fendleri* hydroxylase in transgenic plants

A 1.5 kb EcoRI fragment from pLesq-Hyg comprising the entire coding region of the hydroxylase was gel purified, then cloned into the corresponding site of pBluescript KS (Stratagene). Plasmid DNA from a number of recombinant clones was then restricted with *Pst*I, which should cut only once in the insert and once in the vector polylinker sequence. Release of a 920 bp fragment with *Pst*I indicated the right orientation of the insert for further manipulations. DNA from one such clone was further restricted with *Sal*I, the 5' overhangs filled-in with the Klenow fragment of DNA polymerase I, then cut with *Sac*I. The insert fragment was gel purified, and cloned between the *Sma*I and *Sac*I sites of pBI121 (Clontech) behind the cauliflower mosaic virus 35S promoter. After checking that the sequence of the junction between insert and vector DNA was appropriate, plasmid DNA from a recombinant clone was used to transform *A. tumefaciens* (GV3101). Kanamycin resistant colonies were then used for *in planta* transformation of *A. thaliana* as previously described.

DNA was extracted from kanamycin resistant seedlings and used to PCR-amplify selected fragments from the hydroxylase using nested primers. When fragments of the expected size could be amplified, corresponding plants were grown in the greenhouse or 30 on agar plates, and fatty acids extracted from fully expanded leaves, roots and dry seeds. GC-MS analysis was then performed as previously described to characterize the different fatty acid species and

detect accumulation of hydroxy fatty acids in transgenic tissues.

Expression of the *Lesquerella* hydroxylase in yeast

In order to demonstrate that the cloned *L. fendleri* gene encoded a kappa hydroxylase, the gene was expressed in yeast cells under transcriptional control of an inducible promoter and the yeast cells were examined for the presence of hydroxylated fatty acids by GC-MS.

10 In a first step, a lambda genomic clone containing the *L. fendleri* hydroxylase gene was cut with EcoRI, and a resulting 1400 bp fragment containing the coding sequence of the hydroxylase gene was subcloned in the EcoRI site of the 15 pBluescript KS vector (Stratagene). This subclone, pLesqcod, contains the coding region of the *Lesquerella* hydroxylase plus some additional 3' sequence.

20 In a second step, pLesqcod was cut with HindIII and XbaI, and the insert fragment was cloned into the corresponding sites of the yeast expression vector pYes2 (Invitrogen; Figure 12). This subclone, pLesqYes, contains the *L. fendleri* hydroxylase in the sense orientation relative to the 3' side of the 25 GAL1 promoter. This promoter is inducible by the addition of galactose to the growth medium, and is repressed upon addition of glucose. In addition, the vector carries origins of replication allowing the propagation of pLesqYes in both yeast and *E. coli*.

30 Transformation of *S. cerevisiae* host strain CGY2557

Yeast strain CGY2557 (*MATα*, *GAL*⁺, *ura3-52*, *leu2-3*, *trpl*, *ade2-1*, *lys2-1*, *his5*, *can1-100*) was

grown overnight at 28°C in YPD liquid medium (10 g yeast extract, 20 g bacto-peptone, 20 g dextrose per liter), and an aliquot of the culture was inoculated into 100 ml fresh YPD medium and grown until the

5 OD₆₀₀ of the culture was 1. Cells were then collected by centrifugation and resuspended in about 200µl of supernatant. 40µl aliquots of the cell suspension were then mixed with 1-2µg DNA and electroporated in 2 mm-gap cuvettes using a Biorad Gene Pulser 10 instrument set at 600 V, 200 Ω, 25 µF, 160µl YPD was added and the cells were plated on selective medium containing glucose. Selective medium consisted of 15 6.7 g yeast nitrogen base (Difco), 0.4 g casamino acids (Difco), 0.02 g adenine sulfate, 0.03 g L-leucine, 0.02 g L-tryptophan, 0.03 g L-lysine-HCl, 0.03 g L-histidine-HCl, 2% glucose, water to 1 liter. Plates were solidified using 1.5% Difco Bacto-agar. Transformant colonies appeared after 3 to 4 days incubation at 28°C.

20 Expression of the *L. fendleri* hydroxylase in yeast

Independent transformant colonies from the previous experiment were used to inoculate 5 ml of selective medium containing either 2% glucose (gene repressed) or 2% galactose (gene induced) as the 25 sole carbon source. Independent colonies of CGY2557 transformed with pYES2 containing no insert were used as controls.

After 2 days of growth at 28°C, an aliquot of the cultures was used to inoculate 5 ml of fresh 30 selective medium. The new culture was placed at 16°C and grown for 9 days.

Fatty acid analysis of yeast expressing the *L. fendleri* hydroxylase

Cells from 2.5 ml of culture were pelleted at 1800g, and the supernatant was aspirated as completely as possible. Pellets were then dispersed in 1 ml of 1 N methanolic HCl (Supelco, Bellafonte, PA). Transmethylation and derivatization of hydroxy fatty acids were performed as described above. After drying under nitrogen, samples were redissolved in 50 μ l chloroform before being analyzed by GC-MS.

Samples were injected into an SP2330 fused-silica capillary column (30 m x 0.25 mm ID, 0.25 μ m film thickness, Supelco). The temperature profile was 100 - 160°C, 25°C/min, 160 - 230°C, 10°C/min, 230°C, 3 min, 230-100°C, 25°C/min. Flow rate was 0.9 ml/min. Fatty acids were analyzed using a Hewlett-Packard 5971 series Msdetector.

Gas chromatograms of derivatized fatty acid methyl esters from induced cultures of yeast containing pLesqYes contained a novel peak that eluted at 7.6 min (Figure 13). O-TMS methyl ricinoleate eluted at exactly the same position on control chromatograms. This peak was not present in cultures lacking pLesqYes or in cultures containing pLesqYes grown on glucose (repressing conditions) rather than galactose (inducing conditions). Mass spectrometry of the peak (Figure 13) revealed that the peak has the same spectrum as O-TMS methyl ricinoleate. Thus, on the basis of chromatographic retention time and mass spectrum, it was concluded that the peak corresponded to O-TMS methyl ricinoleate. The presence of ricinoleate in the transgenic yeast cultures confirms the identity of the gene as a kappa hydroxylase of this invention.

EXAMPLE 3. OBTAINING OTHER PLANT FATTY ACYL
HYDROXYLASES

The castor fah12 sequence could be used to identify other kappa hydroxylases by methods such as 5 PCR and heterologous hybridization. However, because of the high degree of sequence similarity between $\Delta 12$ desaturases and kappa hydroxylases, the prior art does not teach how to distinguish between the two kinds of enzymes without a functional test such 10 as demonstrating activity in transgenic plants or another suitable host (e.g., transgenic microbial or animal cells). The identification of the *L. fendleri* hydroxylase provided for the development of criteria by which a hydroxylase and a desaturase may be 15 distinguished solely on the basis of deduced amino acid sequence information.

Figures 9A-B show a sequence alignment of the castor and *L. fendleri* hydroxylase sequences with the castor hydroxylase sequence and all publicly 20 available sequences for all plant microsomal $\Delta 12$ fatty acid desaturases. Of the 384 amino acid residues in the castor hydroxylase sequence, more than 95% are identical to the corresponding residue in at least one of the desaturase sequences. 25 Therefore, none of these residues are responsible for the catalytic differences between the hydroxylase and the desaturases. Of the remaining 16 residues in the castor hydroxylase and 14 residues in the *Lesquerella* hydroxylase, all but seven 30 represent instances where the hydroxylase sequence has a conservative substitution compared with one or more of the desaturase sequences, or there is wide variability in the amino acid at that position in the various desaturases. By conservative, it is

meant that the following amino acids are functionally equivalent: Ser/Thr, Ile/Leu/Val/Met, Asp/Glu. Thus, these structural differences also cannot account for the catalytic differences between 5 the desaturases and hydroxylases. This leaves just seven amino acid residues where both the castor hydroxylase and the *Lesquerella* hydroxylase differ from all of the known desaturases and where all of the known microsomal Δ_{12} desaturases have the identical amino acid residue. These residues occur at positions 69, 111, 155, 226, 304, 331 and 333 of the alignment in Figure 9. Therefore, these seven sites distinguish hydroxylases from desaturases. Based on this analysis, the present inventors 10 believe that any enzyme with greater than 60% sequence identity to one of the enzymes listed in Figure 9 can be classified as a hydroxylase if it differs from the sequence of the desaturases at 15 these seven positions. Because of slight differences in the number of residues in a particular protein, the numbering may vary from protein to protein but the intent of the number system will be evident if the protein in question is aligned with the castor hydroxylase using the numbering system shown herein. 20 Thus, in conjunction with the methods for using the *Lesquerella* hydroxylase gene to isolate homologous genes, the structural criterion disclosed here teaches how to isolate and identify plant kappa hydroxylase genes for the purpose of genetically 25 modifying fatty acid composition as disclosed herein.

EXAMPLE 4 - USING HYDROXYLASES TO ALTER THE LEVEL OF FATTY ACID UNSATURATION

Evidence that kappa hydroxylases of this invention can be used to alter the level of fatty acid unsaturation was obtained from the analysis of transgenic plants that expressed the castor hydroxylase under control of the cauliflower mosaic virus promoter. The construction of the plasmids and the production of transgenic *Arabidopsis* plants was described in Example 1 (above). The fatty acid composition of seed lipids from wild type and six transgenic lines (1-2/a, 1-2/b, 1-3/b, 4F, 7E, 7F) is shown in Table 2.

Table 2. Fatty acid composition of lipids from *Arabidopsis* seeds. The asterisk (*) indicates that for some of these samples, the 18:3 and 20:1 peaks overlapped on the gas chromatograph and, therefore, the total amount of these two fatty acids is reported.

TABLE 2

Fatty acid	WT	1-2/a	1-2/b	1-3/b	4F	7E	7F
16:0	10.3	8.6	9.5	8.4	8.1	8.4	9
18:0	3.5	3.8	3.9	3.3	3.5	3.8	4.2
18:1	14.7	33	34.5	25.5	27.5	30.5	28.5
18:2	32.4	16.9	21	27.5	21.1	20.1	19.8
18:3	13.8	-	14.4	14.8	-	-	-
20:0	1.3	1.6	1	1.1	2.4	1.8	2
20:1	22.5	-	14.1	17.5	-	-	-
18:3 20:1*	-	31.2	-	-	32.1	30.8	30.6
Ricinoleic	0	0.6	0	0.1	0.2	0.7	0.9
Densipolic	0	0.6	0	0.1	0.2	0.5	0.6
Lesquerolic	0	0.2	0	0	0.2	0.2	0.6
Auricolic	0	0.1	0	0	0	0.1	0.1

The results in Table 2 show that expression of the castor hydroxylase in transgenic *Arabidopsis* plants caused a substantial increase in the amount of oleic acid (18:1) in the seed lipids and an 5 approximately corresponding decrease in the amount of linoleic acid (18:2). The average amount of oleic acid in the six transgenic lines was 29.9% versus 14.7% in the wild type.

The precise mechanism by which expression of 10 the castor hydroxylase gene causes increased accumulation of oleic acid is not known. However, an understanding of the mechanism is not required in order to exploit this invention for the directed alteration of plant lipid fatty acid composition. 15 Furthermore, it will be recognized by one skilled in the art that many improvements of this invention may be envisioned. Of particular interest will be the use of other promoters which have high levels of seed-specific expression.

20 Since hydroxylated fatty acids were not detected in the seed lipids of transgenic line 1-2b, it seems likely that it is not the presence of hydroxylated fatty acids per se that causes the effect of the castor hydroxylase gene on desaturase 25 activity. Protein-protein interaction between the hydroxylase and the $\Delta 12$ -oleate desaturase or another protein may be required for the overall reaction (e.g., cytochrome b5) or for the regulation of desaturase activity. For example, interaction 30 between the hydroxylase and this other protein may suppress the activity of the desaturase. In particular, the quaternary structure of the membrane-bound desaturases has not been established. It is possible that these enzymes are active as

dimers or as multimeric complexes containing more than two subunits. Thus, if dimers or multimers form between the desaturase and the hydroxylase, the presence of the hydroxylase in the complex may 5 disrupt the activity of the desaturase.

Transgenic plants may be produced in which the hydroxylase enzyme has been rendered inactive by the elimination of one or more of the histidine residues that have been proposed to bind iron 10 molecules required for catalysis. Several of these histidine residues have been shown to be essential for desaturase activity by site directed mutagenesis (Shanklin et al., 1994). Codons encoding histidine residues in the castor hydroxylase gene will be 15 changed to alanine residues as described by Shanklin et al. (1994). The modified genes will be introduced into transgenic plants of *Arabidopsis*, and possibly other species such as tobacco, by the methods described in Example 1 of this application.

In order to examine the effect on all tissues, the strong constitutive cauliflower mosaic virus promoter may be used to cause transcription of the modified genes. However, it will be recognized that in order to specifically examine the effect of 25 expression of the mutant gene on seed lipids, a seed-specific promoter such as the *B. napus* napin promoter may be used. An expected outcome is that expression of the inactive hydroxylase protein in transgenic plants will inhibit the activity of the 30 endoplasmic reticulum-localized $\Delta 12$ -desaturase. Maximum inhibition will be obtained by expressing high levels of the mutant protein.

In a further embodiment of this invention, mutations that inactivate other hydroxylases, such

as the *Lesquerella* hydroxylase of this invention, may also be useful for decreasing the amount of endoplasmic reticulum-localized $\Delta 12$ -desaturase activity in the same way as the castor gene. In a 5 further embodiment of this invention, similar mutations of desaturase genes may also be used to inactivate endogenous desaturases. Thus, expression of catalytically inactive *fad2* gene from *Arabidopsis* in transgenic *Arabidopsis* may inhibit the activity 10 of the endogenous *fad2* gene product.

Similarly, expression of the catalytically inactive forms of $\Delta 12$ -desaturase from *Arabidopsis* or other plants in transgenic soybean, rapeseed, *Crambe*, *Brassica juncea*, canola, flax, sunflower, 15 safflower, cotton, cuphea, soybean, peanut, coconut, oil palm or corn may lead to inactivation of endogenous $\Delta 12$ -desaturase activity in these plants. In a further embodiment of this invention, expression of catalytically inactive forms of other 20 desaturases such as the $\Delta 15$ -desaturases may lead to inactivation of the corresponding desaturases.

An example of a class of mutants useful in the present invention are "dominant negative" mutants that block the function of a gene at the 25 protein level (Herskowitz, 1987). A cloned gene is altered so that it encodes a mutant product capable of inhibiting the wild type gene product in a cell, thus causing the cell to be deficient in the function of that gene product. Inhibitory variants 30 of a wild type product can be designed because proteins have multiple functional domains that can be mutated independently, e.g., oligomerization, substrate binding, catalysis, membrane association domains or the like. In general, dominant negative

proteins retain an intact, functional subset of the domains of the parent, wild type protein, but have the complement of that subset either missing or altered so as to be nonfunctional.

5 Whatever the precise basis for the inhibitory effect of the castor hydroxylase on desaturation, because the castor hydroxylase has very low nucleotide sequence homology (i.e., about 67%) to the *Arabidopsis fad2* gene (encoding the endoplasmic reticulum-localized $\Delta 12$ -desaturase), the inhibitory 10 effect of this gene, which is provisionally called "protein-mediated inhibition" ("protibition"), may have broad utility because it does not depend on a high degree of nucleotide sequence homology between 15 the transgene and the endogenous target gene. In particular, the castor hydroxylase may be used to inhibit the endoplasmic reticulum-localized $\Delta 12$ -desaturase activity of all higher plants. Of 20 particular relevance are those species used for oil production. These include but are not limited to rapeseed, *Crambe*, *Brassica juncea*, canola, flax, sunflower, safflower, cotton, cuphea, soybean, peanut, coconut, oil palm and corn.

CONCLUDING REMARKS

25 By the above examples, demonstration of critical factors in the production of novel hydroxylated fatty acids by expression of a kappa hydroxylase gene from castor in transgenic plants is described. In addition, a complete cDNA sequence of 30 the *Lesquerella fendleri* kappa hydroxylase is also provided. A full sequence of the castor hydroxylase is also given with various constructs for use in host cells. Through this invention, one can obtain

the amino acid and nucleic acid sequences which encode plant fatty acyl hydroxylases from a variety of sources and for a variety of applications. Also revealed is a novel method by which the level of 5 fatty acid desaturation can be altered in a directed way through the use of genetically altered hydroxylase or desaturase genes.

All publications mentioned in this specification are indicative of the level of skill 10 of those skilled in the art to which this invention pertains. All publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by 15 reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and 20 modifications may be practiced within the scope of the appended claims.

REFERENCES

Arondel, V., B. Lemieux, I. Hwang, S. Gibson, H. Goodman, C.R. Somerville. Map-based cloning of a 25 gene controlling omega-3 fatty acid desaturation in *Arabidopsis*. *Science* 258, 1353-1355 (1992).

Atsmon, D. (1989) Castor, in *Oil Crops of the World*, Robbelen, G., Downey, K.R., and Ashri, A., Eds., McGraw-Hill, New York, pp. 438-447.

Bechtold, N., Ellis, J. and Pelletier, G. (1993) In *Planta Agrobacterium mediated gene transfer by infiltration of adult Arabidopsis thaliana plants.* C.R. Acad. Sci. Paris 316, 1194-1199.

5 Beltz, G.A., Jacobs, K.A., Eickbuch, T.H., Cherbas, P.T., Kafatos, F.C. (1983) Isolation of multigene families and determination of homologies by filter hybridization methods. *Methods in Enzymology* 100, 266-285.

10 Bray, E.A., Naito, S., Pan, N.S., Anderson, E., Dube, P., Beachy, R.N. (1987) Expression of the β -subunit of β -conglycinin in seeds of transgenic plants. *Planta* 172, 364-370.

15 Carlson, K.D., Chaudhry, A., Bagby, M.O (1990) Analysis of oil and meal from *lesquerella fendleri* seed. *J. Am. Oil Chem. Soc.* 67, 438-442.

Ditta, G., Stanfield, S., Corbin, D., Helinski, D.R. (1980) Broad host range DNA cloning system for gram-negative bacteria: Construction of a gene bank of 20 *Rhizobium meliloti*. *Proc. Natl. Acad. Sci. USA* 77, 7347-7351.

Gibson, S., Aronodel, V., Iba, K., Somerville, C.R. (1994) Temperature Regulated Expression of a Gene Encoding a Chloroplast omega-3 Desaturase from 25 *Arabidopsis thaliana*. *Plant Physiol.* 106, 1615-1621.

Gould, S.J., Subramani, S., Scheffler, I.E. (1989) Use of the DNA polymerase chain reaction for

homology probing. Proc. Natl. Acad. Sci. USA 86, 1934-1938.

Herskowitz, I. (1987) Functional inactivation of genes by dominant negative mutations. Nature 329,

5 219-222.

Hirsinger, F. (1989) New oil crops, in *Oil Crops of the World*, Robbelen, G., Downey, K.R., and Ashri, A., Eds., McGraw-Hill, New York, pp. 518-533.

Howling, D., Morris, L.J., Gurr, M.I., James, A.T.

10 (1972) The specificity of fatty acid desaturases and hydroxylases. The dehydrogenation and hydroxylation of monoenoic acids, Biochim. Biophys. Acta 260, 10.

Huyuh, T.V., Young, R.A., Davis, R.W. (1985) Constructing and screening cDNA libraries in λ gt10 and λ gt11. In *DNA Cloning, Vol. 1: A Practical Approach*, (ed) D.M. Glover. IRL Press, Washington DC pp 49-77.

Iba, K., Gibson, S., Nishiuchi, T., Fuse, T., Nishimura, M., Arondel, V., Hugly, S., and

20 Somerville, C. (1993) A gene encoding a chloroplast omega-3 fatty acid desaturase complements alterations in fatty acid desaturation and chloroplast copy number of the fad7 mutant of *Arabidopsis thaliana*. J. Biol. Chem. 268, 24099-24105.

Jones, J.D.G., Shlumukov, L., Carland, F., English, J., Scofield, S., Bishop, G.J., Harrison, K. (1992) Effective vectors for transformation, expression of

heterologous genes, and assaying transposon excision in transgenic plants. *Transgenic Res.* 1, 285-297.

Knutson, D.S., Thompson, G.A., Radke, S.E., Johnson, W.B., Knauf, V.C., Kridl, J.C. (1992) *Proc. Natl.*

5 *Acad. Sci. USA* 89, 2624-2628.

Koncz, C., Schell, J. (1986) The promoter of *T_L*-DNA gene 5 controls the tissue-specific expression of chimeric genes carried by a novel type of *Agrobacterium* binary vector. *Mol. Gen. Genet.* 204,

10 383-396.

Matzke, M., Matzke, A.J.M. (1995) How and why do plants inactivate homologous (Trans)genes? *Plant Physiol.* 107, 679-685.

Miquel, M. Browse, J. (1992) *Arabidopsis* mutants deficient in polyunsaturated fatty acid synthesis. *J. Biol. Chem.* 267, 1502-1509.

Murray, M.G., Thompson, W.F. (1980) Rapid isolation of high molecular weight plant DNA. *Nucl. Acid Res.* 8, 4321-4325.

20 Okuley, J., Lightner, J., Feldman, K., Yadav, N., Lark, E., Browse, J. (1994) *Arabidopsis FAD2* gene encodes the enzyme that is essential for polyunsaturated lipid. *Plant Cell* 6, 147-158.

25 Sambrook, J., Fritsch, E.F., and Maniatis, T., *Molecular Cloning: a Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, 1989.

Shanklin, J., Whittle, E., Fox, B.G. (1994) Eight histidine residues are catalytically essential in a membrane-associated iron enzyme, stearoyl-CoA desaturase, and are conserved in alkane hydroxylase and xylene monooxygenase. *Biochemistry* 33, 12787-12794.

Smith, C.R., Jr. (1985) Unusual seed oils and their fatty acids, in *Fatty Acids*, Pryde E.H., Ed., American Oil Chemists' Society, Champaign, Second edition, pp 29-47.

Töpfer, R., Martini, N., Schell, J. (1995) Modification of plant lipid synthesis. *Science* 268, 681-686.

van de Loo, F.J., Fox, B.G., Somerville, C. (1993) Unusual fatty acids, in *Lipid Metabolism in Plants*, T.S. Moore Jr., Ed., CRC Press, Boca Raton, pp 91-126.

van de Loo, F.N., Turner, S., Somerville, C.R. (1995) An oleate 12-hydroxylase from castor (*Ricinus communis* L.) is a fatty acyl desaturase homolog. *Proc. Natl. Acad. Sci. USA* 92, 6743-6747.

von Heijne, G. (1985) Signal sequences. *J. Mol. Biol.* 184, 99-105.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Somerville, Chris
Broun, Pierre
van de Loo, Frank
Boddupalli, Sekhar S.

(ii) TITLE OF INVENTION: Production of Hydroxylated Fatty Acids in Genetically Modified Plants

(iii) NUMBER OF SEQUENCES: 15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: PILLSBURY MADISON & SUTRO
(B) STREET: 1100 NEW YORK AVENUE, N.W.
(C) CITY: WASHINGTON
(D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20005-3918

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5 inch, 1.44 MB storage
(B) COMPUTER: IBM compatible
(C) OPERATING SYSTEM: DOS 5.0
(D) SOFTWARE: Word Perfect 5.1

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: not yet assigned
(B) FILING DATE: February 6, 1997
(C) CLASSIFICATION:

(2) INFORMATION FOR SEQ ID NO:1

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 543 nucleotides
(B) TYPE: nucleotide
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TATTGGCACC GGCGGCACCA TTCCAACAAT GGATCCCTAG	40
AAAAAGATGA AGTCTTGTC CCACCTAACAGA AAGCTGCAGT	80
CANATGGTAT GTCAAATACC TCAACAAACCC TCTTGGACGC	120
ATTCTGGTGT TAACAGTTCA GTTTATCCTC GGGTGGCCTT	160

TGTATCTAGC CTTAATGTA TCAGGTAGAC CTTATGATGG	200
TTTCGCTTCA CATTCTTCC CTCATGCACC TATCTTTAAG	240
GACCGTGAAC GTCTCCAGAT ATACATCTCA GATGCTGGTA	280
TTCTAGCTGT, CTGTTATGGT CTTTACCGTT ACGCTGCTTC	320
ACAAGGATTG ACTGCTATGA TCTGCGTCTA CGGAGTACCG	360
CTTTTGATAG TGAACTTTT CCTTGTCTTG GTCACTTTCT	400
TGCAGCACAC TCATCCTTCA TTACCTCACT ATGATTCAAC	440
CGAGTGGGAA TGGATTAGAG GAGCTTGTT TACGGTAGAC	480
AGAGACTATG GAATCTTGAA CAAGGTGTTT CACAACATAA	520
CAGACACCCA CGTAGCACAC CAC	543

(2) INFORMATION FOR SEQ ID NO:2

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 544 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TATAGGCACC GGAGGCACCA TTCCAACACA GGATCCCTCG	40
AAAGAGATGA AGTATTTGTC CCAAAGCAGA AATCCGCAAT	80
CAAGTGGTAC GGCGAATACC TCAACAACCC TCCTGGTCGC	120
ATCATGATGT TAACTGTCCA GTTCGTCTC GGATGCCCT	160
TGTACTTAGC CTTCAACGTT TCTGGCAGAC CCTACAATGG	200
TTTCGCTTCC CATTCTTCC CCAATGCTCC TATCTACAAC	240
GACCGTGAAC GCCTCCAGAT TTACATCTCT GATGCTGGTA	280
TTCTAGCCGT CTGTTATGGT CTTTACCGTT ACGCTGTTGC	320
ACAAGGACTA GCCTCAATGA TCTGTCTAAA CGGAGTTCCG	360
CTTCTGATAG TTAACCTTTT CCTCGTCTTG ATCACTTACT	400

TACAACACAC TCACCCTGCG TTGCCTCACT ATGATTCA	440
AGAGTGGGAT TGGCTTAGAG GAGCTTAGC TACTGTAGAC	480
AGAGACTATG GAATCTTGAA CAAGGTGTC CATAACATCA	520
CAGACACCCA CGTCGCACAC CACT	544

(2) INFORMATION FOR SEQ ID NO:3

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1855 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATGAAGCTTT ATAAGAAGTT AGTTTCTCT GGTGACAGAG	40
AAATTNTGTC AATTGGTAGT GACAGTTGAA GCAACAGGAA	80
CAACAAGGAT GGTTGGTGNT GATGCTGATG TGGTGATGTG	120
TTATTCATCA AATACTAAAT ACTACATTAC TTGTTGCTGC	160
CTACTTCTCC TATTCCTCC GCCACCCATT TTGGACCCAC	200
GANCCTTCCA TTTAAACCT CTCTCGTGCT ATTCAACCAGA	240
AGAGAAGCCA AGAGAGAGAG AGAGAGAATG TTCTGAGGAT	280
CATTGTCTTC TTCATCGTTA TTAACGTAAG TTTTTTTGAA	320
CCACTCATAT CTAAAATCTA GTACATGCAA TAGATTAATG	360
ACTGTTCTT CTTTGATAT TTTCAGCTTC TTGAATTCAA	400
GATGGGTGCT GGTGGAAGAA TAATGGTTAC CCCCTCTTCC	440
AAGAAATCAG AAACTGAAGC CCTAAAACGT GGACCATGTG	480
AGAAACCACC ATTCACTGTT AAAGATCTGA AGAAAGCAAT	520
CCCACAGCAT TGTTCAAGC GCTCTATCCC TCGTTCTTC	560
TCCTACCTTC TCACAGATAT CACTTAGTT TCTTGCTTCT	600
ACTACGTTGC CACAAATTAC TTCTCTCTTC TTCCCTCAGCC	640

TCTCTCTACT TACCTAGCTT GGCCTCTCTA TTGGGTATGT	680
CAAGGCTGTG TCTTAACCGG TATCTGGTC ATTGCCATG	720
AATGTGGTCA CCATGCATTG AGTGAATATC AATGGTAGA	760
TGACACTGTT GGTTTATCT TCCATTCTT CCTTCTCGTC	800
CCTTACTTCT CCTGGAAATA CAGTCATCGT CGTCACCATT	840
CCAACAATGG ATCTCTCGAG AAAGATGAAG TCTTGTC	880
ACCGAAGAAA GCTGCAGTCA AATGGTATGT TAAATACCTC	920
AACAACCCTC TTGGACGCAT TCTGGTGTAA ACAGTTCA	960
TTATCCTCGG GTGGCCTTG TATCTAGCCT TTAATGTATC	1000
AGGTAGACCT TATGATGGTT TCGCTTCACA TTTCTCCCT	1040
CATGCACCTA TCTTAAAGA CCGAGAACGC CTCCAGATAT	1080
ACATCTCAGA TGCTGGTATT CTAGCTGTCT GTTATGGTCT	1120
TTACCGTTAC GCTGCTTCAC AAGGATTGAC TGCTATGATC	1160
TGCGTCTATG GAGTACCGCT TTTGATAGTG AAC	1200
TTGTCTTGGT AAC	1240
ACCTCATTAT GATTCAACCG AGTGGGAATG GATTAGAGGA	1280
GCTTGGTTA CGGTAGACAG AGACTATGGA ATATTGAACA	1320
AGGTGTTCCA TAACATAACA GACACACATG TGGCTCATCA	1360
TCTCTTGCA ACTATACCGC ATTATAACGC AATGGAAAGCT	1400
ACAGAGGCGA TAAAGCCAAT ACTTGGTGAT TACTACCACT	1440
TCGATGGAAC ACCGTGGTAT GTGCCATGT ATAGGGAAGC	1480
AAAGGAGTGT CTCTATGTAG AACCGGATAC GGAACGTGGG	1520
AAGAAAGGTG TCTACTATTA CAACAATAAG TTATGAGGCT	1560
GATAGGGCGA GAGAAGTGCA ATTATCAATC TTCATTCCA	1600
TGTTTTAGGT GTCTTGTAA AGAAGCTATG CTTTGTGTTCA	1640
ATAATCTCAG AGTCCATNTA GTTGTGTTCT GGTGCATTT	1680

GCCTAGTTAT GTGGTGTGCGG AAGTTAGTGT TCAAACTGCT	1720
TCCTGCTGTG CTGCCAGTG AAGAACAAAGT TTACGTGTTT	1760
AAAATACTCG GAACGAATTG ACCACAANAT ATCCAAAACC	1800
GGCTATCCGA ATTCCATATC CGAAAACCGG ATATCCAAAT	1840
TTCCAGAGTA CTTAG	1855

(2) INFORMATION FOR SEQ ID NO:4

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 384 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met	Gly	Ala	Gly	Gly	Arg	Ile	Met	Val	Thr
						5			10
Pro	Ser	Ser	Lys	Lys	Ser	Glu	Thr	Glu	Ala
						15			20
Leu	Lys	Arg	Gly	Pro	Cys	Glu	Lys	Pro	Pro
						25			30
Phe	Thr	Val	Lys	Asp	Leu	Lys	Lys	Ala	Ile
						35			40
Pro	Gln	His	Cys	Phe	Lys	Arg	Ser	Ile	Pro
						45			50
Arg	Ser	Phe	Ser	Tyr	Leu	Leu	Thr	Asp	Ile
						55			60
Thr	Leu	Val	Ser	Cys	Phe	Tyr	Tyr	Val	Ala
						65			70
Thr	Asn	Tyr	Phe	Ser	Leu	Leu	Pro	Gln	Pro
						75			80
Leu	Ser	Thr	Tyr	Leu	Ala	Trp	Pro	Leu	Tyr
						85			90
Trp	Val	Cys	Gln	Gly	Cys	Val	Leu	Thr	Gly
						95			100

Ile Trp Val Ile Gly His Glu Cys Gly His
105 110

His Ala Phe Ser Asp Tyr Gln Trp Val Asp
115 120

Asp Thr Val Gly Phe Ile Phe His Ser Phe
125 130

Leu Leu Val Pro Tyr Phe Ser Trp Lys Tyr
135 140

Ser His Arg Arg His His Ser Asn Asn Gly
145 150

Ser Leu Glu Lys Asp Glu Val Phe Val Pro
155 160

Pro Lys Lys Ala Ala Val Lys Trp Tyr Val
165 170

Lys Tyr Leu Asn Asn Pro Leu Gly Arg Ile
175 180

Leu Val Leu Thr Val Gln Phe Ile Leu Gly
185 190

Trp Pro Leu Tyr Leu Ala Phe Asn Val Ser
195 200

Gly Arg Pro Tyr Asp Gly Phe Ala Ser His
205 210

Phe Phe Pro His Ala Pro Ile Phe Lys Asp
215 220

Arg Glu Arg Leu Gln Ile Tyr Ile Ser Asp
225 230

Ala Gly Ile Leu Ala Val Cys Tyr Gly Leu
235 240

Tyr Arg Tyr Ala Ala Ser Gln Gly Leu Thr
245 250

Ala Met Ile Cys Val Tyr Gly Val Pro Leu
255 260

Leu Ile Val Asn Phe Phe Leu Val Leu Val
265 270

Thr Phe Leu Gln His Thr His Pro Ser Leu
275 280

Pro His Tyr Asp Ser Thr Glu Trp Glu Trp
285 290

Ile Arg Gly Ala Leu Val Thr Val Asp Arg
295 300

Asp Tyr Gly Ile Leu Asn Lys Val Phe His
305 310

Asn Ile Thr Asp Thr His Val Ala His His
315 320

Leu Phe Ala Thr Ile Pro His Tyr Asn Ala
325 330

Met Glu Ala Thr Glu Ala Ile Lys Pro Ile
335 340

Leu Gly Asp Tyr Tyr His Phe Asp Gly Thr
345 350

Pro Trp Tyr Val Ala Met Tyr Arg Glu Ala
355 360

Lys Glu Cys Leu Tyr Val Glu Pro Asp Thr
365 370

Glu Arg Gly Lys Lys Gly Val Tyr Tyr Tyr
375 380

Asn Asn Lys Leu

(2) INFORMATION FOR SEQ ID NO:5

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 387 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Gly Gly Gly Gly Arg Met Ser Thr Val
5 10

Ile Thr Ser Asn Asn Ser Glu Lys Lys Gly
15 20

Gly Ser Ser His Leu Lys Arg Ala Pro His
25 30

Thr Lys Pro Pro Phe Thr Leu Gly Asp Leu
35 40

Lys Arg Ala Ile Pro Pro His Cys Phe Glu
45 50

Arg Ser Phe Val Arg Ser Phe Ser Tyr Val
55 60

Ala Tyr Asp Val Cys Leu Ser Phe Leu Phe
65 70

Tyr Ser Ile Ala Thr Asn Phe Phe Pro Tyr
75 80

Ile Ser Ser Pro Leu Ser Tyr Val Ala Trp
85 90

Leu Val Tyr Trp Leu Phe Gln Gly Cys Ile
95 100

Leu Thr Gly Leu Trp Val Ile Gly His Glu
105 110

Cys Gly His His Ala Phe Ser Glu Tyr Gln
115 120

Leu Ala Asp Asp Ile Val Gly Leu Ile Val
125 130

His Ser Ala Leu Leu Val Pro Tyr Phe Ser
135 140

Trp Lys Tyr Ser His Arg Arg His His Ser
145 150

Asn Ile Gly Ser Leu Glu Arg Asp Glu Val
155 160

Phe Val Pro Lys Ser Lys Ser Lys Ile Ser
165 170

Trp Tyr Ser Lys Tyr Ser Asn Asn Pro Pro
175 180

Gly Arg Val Leu Thr Leu Ala Ala Thr Leu
185 190

Leu Leu Gly Trp Pro Leu Tyr Leu Ala Phe
195 200

Asn Val Ser Gly Arg Pro Tyr Asp Arg Phe
205 210

Ala Cys His Tyr Asp Pro Tyr Gly Pro Ile
215 220

Phe Ser Glu Arg Glu Arg Leu Gln Ile Tyr
225 230

Ile Ala Asp Leu Gly Ile Phe Ala Thr Thr
235 240

Phe Val Leu Tyr Gln Ala Thr Met Ala Lys
245 250

Gly Leu Ala Trp Val Met Arg Ile Tyr Gly
255 260

Val Pro Leu Leu Ile Val Asn Cys Phe Leu
265 270

Val Met Ile Thr Tyr Leu Gln His Thr His
275 280

Pro Ala Ile Pro Arg Tyr Gly Ser Ser Glu
285 290

Trp Asp Trp Leu Arg Gly Ala Met Val Thr
295 300

Val Asp Arg Asp Tyr Gly Val Leu Asn Lys
305 310

Val Phe His Asn Ile Ala Asp Thr His Val
315 320

Ala His His Leu Phe Ala Thr Val Pro His
325 330

Tyr His Ala Met Glu Ala Thr Lys Ala Ile
335 340

Lys Pro Ile Met Gly Glu Tyr Tyr Arg Tyr
345 350

Asp Gly Thr Pro Phe Tyr Lys Ala Leu Trp
355 360

Arg Glu Ala Lys Glu Cys Leu Phe Val Glu
365 370

Pro Asp Glu Gly Ala Pro Thr Gln Gly Val
375 380

Phe Trp Tyr Arg Asn Lys Tyr
385

(2) INFORMATION FOR SEQ ID NO:6

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 383 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gly Ala Gly Gly Arg Met Pro Val Pro
5 10

Thr Ser Ser Lys Lys Ser Glu Thr Asp Thr
15 20

Thr Lys Arg Val Pro Cys Glu Lys Pro Pro
25 30

Phe Ser Val Gly Asp Leu Lys Lys Ala Ile
35 40

Pro Pro His Cys Phe Lys Arg Ser Ile Pro
45 50

Arg Ser Phe Ser Tyr Leu Ile Ser Asp Ile
55 60

Ile Ile Ala Ser Cys Phe Tyr Tyr Val Ala
65 70

Thr Asn Tyr Phe Ser Leu Leu Pro Gln Pro
75 80

Leu Ser Tyr Leu Ala Trp Pro Leu Tyr Trp
85 90

Ala Cys Gln Gly Cys Val Leu Thr Gly Ile
95 100

Trp Val Ile Ala His Glu Cys Gly His His
105 110

Ala Phe Ser Asp Tyr Gln Trp Leu Asp Asp
115 120

Thr Val Gly Leu Ile Phe His Ser Phe Leu
125 130

Leu Val Pro Tyr Phe Ser Trp Lys Tyr Ser
135 140

His Arg Arg His His Ser Asn Thr Gly Ser
145 150

Leu Glu Arg Asp Glu Val Phe Val Pro Lys
155 160

Gln Lys Ser Ala Ile Lys Trp Tyr Gly Lys
165 170

Tyr Leu Asn Asn Pro Leu Gly Arg Ile Met
175 180

Met Leu Thr Val Gln Phe Val Leu Gly Trp
185 190

Pro Leu Tyr Leu Ala Phe Asn Val Ser Gly
195 200

Arg Pro Tyr Asp Gly Phe Ala Cys His Phe
205 210

Phe Pro Asn Ala Pro Ile Tyr Asn Asp Arg
215 220

Glu Arg Leu Gln Ile Tyr Leu Ser Asp Ala
225 230

Gly Ile Leu Ala Val Cys Phe Gly Leu Tyr
235 240

Arg Tyr Ala Ala Ala Gln Gly Met Ala Ser
245 250

Met Ile Cys Leu Tyr Gly Val Pro Leu Leu
255 260

Ile Val Asn Ala Phe Leu Val Leu Ile Thr
265 270

Tyr Leu Gln His Thr His Pro Ser Leu Pro
275 280

His Tyr Asp Ser Ser Glu Trp Asp Trp Leu
285 290

Arg Gly Ala Leu Ala Thr Val Asp Arg Asp
295 300

Tyr Gly Ile Leu Asn Lys Val Phe His Asn
305 310

Ile Thr Asp Thr His Val Ala His His Leu
315 320

Phe Ser Thr Met Pro His Tyr Asn Ala Met
325 330

Glu Ala Thr Lys Ala Ile Lys Pro Ile Leu
335 340

Gly Asp Tyr Tyr Gln Phe Asp Gly Thr Pro
345 350

Trp Tyr Val Ala Met Tyr Arg Glu Ala Lys
355 360

Glu Cys Ile Tyr Val Glu Pro Asp Arg Glu
365 370

Gly Asp Lys Lys Gly Val Tyr Trp Tyr Asn
375 380

Asn Lys Leu

(2) INFORMATION FOR SEQ ID NO:7

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 384 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Met Gly Ala Gly Gly Arg Met Gln Val Ser
5 10

Pro Pro Ser Lys Lys Ser Glu Thr Asp Asn
15 20

Ile Lys Arg Val Pro Cys Glu Thr Pro Pro
25 30

Phe Thr Val Gly Glu Leu Lys Lys Ala Ile
35 40

Pro Pro His Cys Phe Lys Arg Ser Ile Pro
45 50

Arg Ser Phe Ser His Leu Ile Trp Asp Ile
55 60

Ile Ile Ala Ser Cys Phe Tyr Tyr Val Ala
65 70

Thr Thr Tyr Phe Pro Leu Leu Pro Asn Pro
75 80

Leu Ser Tyr Phe Ala Trp Pro Leu Tyr Trp
85 90

Ala Cys Gln Gly Cys Val Leu Thr Gly Val
95 100

Trp Val Ile Ala His Glu Cys Gly His Ala
105 110

Ala Phe Ser Asp Tyr Gln Trp Leu Asp Asp
115 120

Thr Val Gly Leu Ile Phe His Ser Phe Leu
125 130

Leu Val Pro Tyr Phe Ser Trp Lys Tyr Ser
135 140

His Arg Arg His His Ser Asn Thr Gly Ser
145 150

Leu Glu Arg Asp Glu Val Phe Val Pro Arg
155 160

Arg Ser Gln Thr Ser Ser Gly Thr Ala Ser
165 170

Thr Ser Thr Thr Phe Gly Arg Thr Val Met
175 180

Leu Thr Val Gln Phe Thr Leu Gly Trp Pro
185 190

Leu Tyr Leu Ala Phe Asn Val Ser Gly Arg
195 200

Pro Tyr Asp Gly Gly Phe Ala Cys His Phe
205 210

His Pro Asn Ala Pro Ile Tyr Asn Asp Arg
215 220

Glu Arg Leu Gln Ile Tyr Ile Ser Asp Ala
225 230

Gly Ile Leu Ala Val Cys Tyr Gly Leu Leu
235 240

Pro Tyr Ala Ala Val Gln Gly Val Ala Ser
245 250

Met Val Cys Phe Leu Arg Val Pro Leu Leu
255 260

Ile Val Asn Gly Phe Leu Val Leu Ile Thr
265 270

Tyr Leu Gln His Thr His Pro Ser Leu Pro
275 280

His Tyr Asp Ser Ser Glu Trp Asp Trp Leu
285 290

Arg Gly Ala Leu Ala Thr Val Asp Arg Asp
295 300

Tyr Gly Ile Leu Asn Gln Gly Phe His Asn
305 310

Ile Thr Asp Thr His Glu Ala His His Leu
315 320

Phe Ser Thr Met Pro His Tyr His Ala Met
325 330

Glu Ala Thr Lys Ala Ile Lys Pro Ile Leu
335 340

Gly Glu Tyr Tyr Gln Phe Asp Gly Thr Pro
345 350

Val Val Lys Ala Met Trp Arg Glu Ala Lys
355 360

Glu Cys Ile Tyr Val Glu Pro Asp Arg Gln
365 370

Gly Glu Lys Lys Gly Val Phe Trp Tyr Asn
375 380

Asn Lys Leu Xaa

(2) INFORMATION FOR SEQ ID NO:8

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 309 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ser Leu Leu Thr Ser Phe Ser Tyr Val Val
5 10

Tyr Asp Leu Ser Phe Ala Phe Ile Phe Tyr
15 20

Ile Ala Thr Thr Tyr Phe His Leu Leu Pro
25 30

Gln Pro Phe Ser Leu Ile Ala Trp Pro Ile
35 40

Tyr Trp Val Leu Gln Gly Cys Leu Leu Thr
45 50

Arg Val Cys Gly His His Ala Phe Ser Lys
55 60

Tyr Gln Trp Val Asp Asp Val Val Gly Leu
65 70

Thr Leu His Ser Thr Leu Leu Val Pro Tyr
75 80

Phe Ser Trp Lys Ile Ser His Arg Arg His
85 90

His Ser Asn Thr Gly Ser Leu Asp Arg Asp
95 100

Glu Arg Val Lys Val Ala Trp Phe Ser Lys
105 110

Tyr Leu Asn Asn Pro Leu Gly Arg Ala Val
115 120

Ser Leu Leu Val Thr Leu Thr Ile Gly Trp
125 130

Pro Met Tyr Leu Ala Phe Asn Val Ser Gly
135 140

Arg Pro Tyr Asp Ser Phe Ala Ser His Tyr
145 150

His Pro Tyr Arg Val Arg Leu Leu Ile Tyr
155 160

Val Ser Asp Val Ala Leu Phe Ser Val Thr
165 170

Tyr Ser Leu Tyr Arg Val Ala Thr Leu Lys
175 180

Gly Leu Val Trp Leu Leu Cys Val Tyr Gly
185 190

Val Pro Leu Leu Ile Val Asn Gly Phe Leu
195 200

Val Thr Ile Thr Tyr Leu Arg Val His Tyr
205 210

Asp Ser Ser Glu Trp Asp Trp Leu Lys Gly
215 220

Ala Leu Ala Thr Met Asp Arg Asp Tyr Gly
225 230

Ile Leu Asn Lys Val Phe His His Ile Thr
235 240

Asp Thr His Val Ala His His Leu Phe Ser
245 250

Thr Met Pro His Tyr His Leu Arg Val Lys
255 260

Pro Ile Leu Gly Glu Tyr Tyr Gln Phe Asp
265 270

Asp Thr Pro Phe Tyr Lys Ala Leu Trp Arg
275 280

Glu Ala Arg Glu Cys Leu Tyr Val Glu Pro
285 290

Asp Glu Gly Thr Ser Glu Lys Gly Val Tyr
295 300

Trp Tyr Arg Asn Lys Tyr Leu Arg Val
305

(2) INFORMATION FOR SEQ ID NO:9

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 302 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Phe Ser Tyr Val Val Tyr Asp Leu Thr Ile
5 10

Ala Phe Cys Leu Tyr Tyr Val Ala Thr His
15 20

Tyr Phe His Leu Leu Pro Gly Pro Leu Ser
25 30

Phe Arg Gly Met Ala Ile Tyr Trp Ala Val
35 40

Gln Gly Cys Ile Leu Thr Gly Val Trp Val
45 50

Val Ala Phe Ser Asp Tyr Gln Leu Leu Asp
55 60

Asp Ile Val Gly Leu Ile Leu His Ser Ala
65 70

Leu Leu Val Pro Tyr Phe Ser Trp Lys Tyr
75 80

Ser His Arg Arg His His Ser Asn Thr Gly
85 90

Ser Leu Glu Arg Asp Glu Val Phe Val Pro
95 100

Lys Val Ser Lys Tyr Leu Asn Asn Pro Pro
105 110

Gly Arg Val Leu Thr Leu Ala Val Thr Leu
115 120

Thr Leu Gly Trp Pro Leu Tyr Leu Ala Leu
125 130

Asn Val Ser Gly Arg Pro Tyr Asp Arg Phe
135 140

Ala Cys His Tyr Asp Pro Tyr Gly Pro Ile
145 150

Tyr Ser Val Ile Ser Asp Ala Gly Val Leu
155 160

Ala Val Val Tyr Gly Leu Phe Arg Leu Ala
165 170

Met Ala Lys Gly Leu Ala Trp Val Val Cys
175 180

Val Tyr Gly Val Pro Leu Leu Val Val Asn
185 190

Gly Phe Leu Val Leu Ile Thr Phe Leu Gln
195 200

His Thr His Val Ser Glu Trp Asp Trp Leu
205 210

Arg Gly Ala Leu Ala Thr Val Asp Arg Asp
215 220

Tyr Gly Ile Leu Asn Lys Val Phe His Asn
225 230

Ile Thr Asp Thr His Val Ala His His Leu
235 240

Phe Ser Thr Met Pro His Tyr His Ala Met
245 250

Glu Ala Thr Val Glu Tyr Tyr Arg Phe Asp
255 260

Glu Thr Pro Phe Val Lys Ala Met Trp Arg
265 270

Glu Ala Arg Glu Cys Ile Tyr Val Glu Pro
275 280

Asp Gln Ser Thr Glu Ser Lys Gly Val Phe
285 290

Trp Tyr Asn Asn Lys Leu Ala Met Glu Ala
295 300

Thr Val

(2) INFORMATION FOR SEQ ID NO:10

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 372 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Gly Ala Gly Gly Arg Met Thr Glu Lys
5 10

Glu Arg Glu Lys Gln Glu Gln Leu Ala Arg
15 20

Ala Thr Gly Gly Ala Ala Met Gln Arg Ser
25 30

Pro Val Glu Lys Pro Pro Phe Thr Leu Gly
35 40

Gln Ile Lys Lys Ala Ile Pro Pro His Cys
45 50

Phe Glu Arg Ser Val Leu Lys Ser Phe Ser
55 60

Tyr Val Val His Asp Leu Val Ile Ala Ala
65 70

Ala Leu Leu Tyr Phe Ala Leu Ala Ile Ile
75 80

Pro Ala Leu Pro Ser Pro Leu Arg Tyr Ala
85 90

Ala Trp Pro Leu Tyr Trp Ile Ala Gln Gly
95 100

Ala Phe Ser Asp Tyr Ser Leu Leu Asp Asp
105 110

Val Val Gly Leu Val Leu His Ser Ser Leu
115 120

Met Val Pro Tyr Phe Ser Trp Lys Tyr Ser
125 130

His Arg Arg His His Ser Asn Thr Gly Ser
135 140

Leu Glu Arg Asp Glu Val Phe Val Pro Lys
145 150

Lys Lys Glu Ala Leu Pro Trp Tyr Thr Pro
155 160

Tyr Val Tyr Asn Asn Pro Val Gly Arg Val
165 170

Val His Ile Val Val Gln Leu Thr Leu Gly
175 180

Trp Pro Leu Tyr Leu Ala Thr Asn Ala Ser
185 190

Gly Arg Pro Tyr Pro Arg Phe Ala Cys His
195 200

Phe Asp Pro Tyr Gly Pro Ile Tyr Asn Asp
205 210

Arg Glu Arg Ala Gln Ile Phe Val Ser Asp
215 220

Ala Gly Val Val Ala Val Ala Phe Gly Leu
225 230

Tyr Lys Leu Ala Ala Ala Phe Gly Val Trp
235 240

Trp Val Val Arg Val Tyr Ala Val Pro Leu
245 250

Leu Ile Val Asn Ala Trp Leu Val Leu Ile
255 260

Thr Tyr Leu Gln His Thr His Pro Ser Leu
265 270

Pro His Tyr Asp Ser Ser Glu Trp Asp Trp
275 280

Leu Arg Gly Ala Leu Ala Thr Met Asp Arg
285 290

Asp Tyr Gly Ile Leu Asn Arg Val Phe His
295 300
Asn Ile Thr Asp Thr His Val Ala His His
305 310
Leu Phe Ser Thr Met Pro His Tyr His Ala
315 320
Met Glu Ala Thr Lys Ala Ile Arg Pro Ile
325 330
Leu Gly Asp Tyr Tyr His Phe Asp Pro Thr
335 340
Pro Val Ala Lys Ala Thr Trp Arg Glu Ala
345 350
Gly Glu Cys Ile Tyr Val Glu Pro Glu Asp
355 360
Arg Lys Gly Val Phe Trp Tyr Asn Lys Lys
365 370
Phe Xaa

(2) INFORMATION FOR SEQ ID NO:11

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 224 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Trp Val Met Ala His Asp Cys Gly His His
5 10
Ala Phe Ser Asp Tyr Gln Leu Leu Asp Asp
15 20
Val Val Gly Leu Ile Leu His Ser Cys Leu
25 30
Leu Val Pro Tyr Phe Ser Trp Lys His Ser
35 40
His Arg Arg His His Ser Asn Thr Gly Ser
45 50

Leu Glu Arg Asp Glu Val Phe Val Pro Lys
55 60

Lys Lys Ser Ser Ile Arg Trp Tyr Ser Lys
65 70

Tyr Leu Asn Asn Pro Pro Gly Arg Ile Met
75 80

Thr Ile Ala Val Thr Leu Ser Leu Gly Trp
85 90

Pro Leu Tyr Leu Ala Phe Asn Val Ser Gly
95 100

Arg Pro Tyr Asp Arg Phe Ala Cys His Tyr
105 110

Asp Pro Tyr Gly Pro Ile Tyr Asn Asp Arg
115 120

Glu Arg Ile Glu Ile Phe Ile Ser Asp Ala
125 130

Gly Val Leu Ala Val Thr Phe Gly Leu Tyr
135 140

Gln Leu Ala Ile Ala Lys Gly Leu Ala Trp
145 150

Val Val Cys Val Tyr Gly Val Pro Leu Leu
155 160

Val Val Asn Ser Phe Leu Val Leu Ile Thr
165 170

Phe Leu Gln His Thr His Pro Ala Leu Pro
175 180

His Tyr Asp Ser Ser Glu Trp Asp Trp Leu
185 190

Arg Gly Ala Leu Ala Thr Val Asp Arg Asp
195 200

Tyr Gly Ile Leu Asn Lys Val Phe His Asn
205 210

Ile Thr Asp Thr Gln Val Ala His His Leu
215 220

Phe Thr Met Pro

(2) INFORMATION FOR SEQ ID NO:12

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCTCTTTGT GCGCTCATTC

20

(2) INFORMATION FOR SEQ ID NO:13

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CGGTACCAAGA AAACGCCTTG

20

(2) INFORMATION FOR SEQ ID NO:14

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 20 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TAYWSNCAYM GNMGNCAYCA

20

(2) INFORMATION FOR SEQ ID NO:15

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 21 nucleotides
 - (B) TYPE: nucleotide
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

RTGRTGNGCN ACRTGNGTRT C

21

WHAT IS CLAIMED IS:

1. A method of altering an amount of an unsaturated fatty acid in a seed of a plant comprising: decreasing a fatty acid desaturase activity in the seed by genetic manipulation of at least one of fatty acid desaturase or fatty acid hydroxylase.
2. The method of Claim 1, wherein an endogenous gene for said fatty acid hydroxylase is mutated and thereby decreases fatty acid hydroxylase activity in the seed.
3. The method of Claim 1, wherein said plant is transformed with a nucleic acid containing a sequence which encodes a fatty acid hydroxylase or derivative thereof.
4. The method of Claim 3, wherein said derivative is a dominant negative mutant which thereby alters the amount of the unsaturated fatty acid in the seed.
5. The method of Claim 3, wherein said derivative is a mutant fatty acid hydroxylase in which one or more essential histidine residues have been mutated which thereby alters the amount of the unsaturated fatty acid in the seed.
6. The method of Claim 1, wherein an endogenous gene for said fatty acid desaturase is mutated and thereby decreases fatty acid desaturase activity in the seed.

7. The method of Claim 1, wherein said plant is transformed with a nucleic acid containing a sequence which encodes a fatty acid desaturase or derivative thereof.

8. The method of Claim 7, wherein said derivative is a dominant negative mutant which thereby alters the amount of the unsaturated fatty acid in the seed.

9. The method of Claim 7, wherein said derivative is a mutant fatty acid desaturase in which one or more essential histidine residues have been mutated which thereby alters the amount of the unsaturated fatty acid in the seed.

10. The method of Claim 1, wherein said plant is selected from the group consisting of rapeseed, Crambe, Brassica juncea, canola, flax, sunflower, safflower, cotton, cuphea, soybean, peanut, coconut, oil palm and corn.

11. A method of altering an amount of a unsaturated fatty acid comprising:

(a) transforming a plant cell with a nucleic acid containing a sequence which encodes a fatty acid hydroxylase or a dominant negative mutant of fatty acid hydroxylase or a dominant negative mutant of fatty acid desaturase,

(b) growing a seed-bearing plant from the transformed plant cell of step (a), and

(c) identifying a seed from the plant of step (b) with the altered amount of the unsaturated fatty acid in the seed.

12. The method of Claim 11, wherein said nucleic acid contains a sequence which encodes the dominant negative mutant of fatty acid hydroxylase in which one or more essential histidine residues have been mutated.

13. The method of Claim 11, wherein said nucleic acid contains a sequence which encodes the dominant negative mutant of fatty acid hydroxylase which thereby alters the amount of the unsaturated fatty acid in the seed.

14. The method of Claim 11, wherein said nucleic acid contains a sequence which encodes the dominant negative mutant of fatty acid desaturase in which one or more essential histidine residues have been mutated.

15. The method of Claim 11, wherein said nucleic acid contains a sequence which encodes the dominant negative mutant of fatty acid desaturase which thereby alters the amount of the unsaturated fatty acid in the seed.

16. The method of Claim 11, wherein said plant is selected from the group consisting of rapeseed, *Crambe*, *Brassica juncea*, canola, flax, sunflower, safflower, cotton, cuphea, soybean, peanut, coconut, oil palm and corn.

17. A recombinant nucleic acid suitable for use in Claim 1, wherein said nucleic acid contains a sequence encoding a fatty acid hydroxylase with an

amino acid identity of 60% or greater to SEQ ID NO:4.

18. The recombinant nucleic acid of Claim 17, wherein the amino acid identity is 90% or greater to SEQ ID NO:4.

19. The recombinant nucleic acid of Claim 17, wherein the amino acid identity is 100% of SEQ ID NO:4.

20. The recombinant nucleic acid of Claim 17, wherein said nucleic acid contains a sequence having a nucleotide identity of 90% or greater to SEQ ID NO:1, 2 or 3.

21. The recombinant nucleic acid of Claim 17, wherein said nucleic acid contains SEQ ID NO:1, 2 or 3.

22. The recombinant nucleic acid of Claim 17, wherein said sequence is obtainable from a plant species producing a hydroxylated fatty acid.

23. A recombinant nucleic acid suitable for use in Claim 1, wherein said nucleic acid contains a sequence encoding at least one of fatty acid desaturase or fatty acid hydroxylase.

24. The recombinant nucleic acid of Claim 23, wherein said sequence is obtainable from *Ricinus communis* (L.) (castor).

25. The recombinant nucleic acid of Claim 23, wherein said sequence is obtainable from *Lesquerella fendleri*.

26. The recombinant nucleic acid of Claim 23, wherein said nucleic acid contains a sequence encoding at least one of fatty acid desaturase or fatty acid hydroxylase in which one or more essential histidine residues have been mutated.

27. The method of Claim 1 further comprising: processing the seed containing the altered amount of the unsaturated fatty acid to obtain oil and/or seed meal.

28. Oil obtained by the method of Claim 27.

29. Seed meal obtained by the method of Claim 27.

30. Plant obtained by the method of Claim 1.

31. The method of Claim 11 further comprising: processing the seed containing the altered amount of the unsaturated fatty acid to obtain oil and/or seed meal.

32. Oil obtained by the method of Claim 31.

33. Seed meal obtained by the method of Claim 31.

34. Plant obtained by the method of Claim 11.


09/117921

WO 97/30582


PCT/US97/02187

1/15

Figure 1A



1B



SUBSTITUTE SHEET (RULE 26)


09/117921

PCT/US97/02187


WO 97/30582

2/15

1C




1D




SUBSTITUTE SHEET (RULE 26)

3/15


09/117921




Ion #2: Mass 299




Ion #3: Mass 270 (characteristic rearrangement ion)



Ion #4: Mass 185 (desaturated analog of Ion #1)



Ion #5: Mass 298 (elongated analog of Ion #3)



Ion #6: Mass 327 (elongated analog of ion





Figure 2

09/117921

4/15


Figure 3




09/117921

5/15

Figure 4A Mass spectrum of peak 10 from figure 3B



4B Mass spectrum of peak 11 from figure 3B




09/117921

6/15


4C

Mass spectrum of peak 12 from figure 3B



4D

Mass spectrum of peak 13 from figure 3B



09/117921

7/15

10	20	30	40	50	60
TATTGSCACC	GGCGGCACCA	TTCCAACAAT	GGATCCCTAG	AAAAAGATGA	AGTCTTGTC
70	80	90	100	110	120
CCACCTAAGA	AAGCTGCAGT	CANATGGTAT	GTCAAATACC	TCAACAAACCC	TCTTGGACGC
130	140	150	160	170	180
ATTCTGGTGT	TAACAGTTCA	GTTTATCCTC	GGGTGGCCTT	TGTATCTAGC	CTTTAATGTA
190	200	210	220	230	240
TCAGGTAGAC	CTTATGATGG	TTTCGCTTCA	CATTTCTTCC	CTCATGCACC	TATCTTTAAG
250	260	270	280	290	300
GACCGTAGAAC	GTCTCCAGAT	ATACATCTCA	GATGCTGGTA	TTCTAGCTGT	CTGTTATGGT
310	320	330	340	350	360
CTTTACCGTT	ACGCTGCTTC	ACAAGGATTG	ACTGCTATGA	TCTGCGTCTA	CGGAGTACCG
370	380	390	400	410	420
CTTTTGATAG	TGAAACTTTT	CCTTGTCTTG	GTCACTTTCT	TGCAGCACAC	TCATCCTTCA
430	440	450	460	470	480
TTACCTCACT	ATGATTCAAC	CGAGTGGGAA	TGGATTAGAG	GAGCTTGTT	TACGGTAGAC
490	500	510	520	530	540
AGAGACTATG	GAATCTTGAA	CAAGGTGTT	CACAACATAA	CAGACACCCA	CGTAGCACAC
550					
CAC					

Figure 5

SUBSTITUTE SHEET (RULE 26)

10	20	30	40	50	60
TATAGGCACC	GGAGGCACCA	TTCCAACACA	GGATCCCTCG	AAAGAGATGA	AGTATTTGTC
70	80	90	100	110	120
CCAAAGCAGA	AATCCGCAAT	CAAGTGCTAC	GGCGAACATCC	TCAACAAACCC	TCCTGGTCGC
130	140	150	160	170	180
ATCATGATGT	TAACTGTCCA	GTTCGTCCTC	GGATGGCCCT	TGTACTTAGC	CTTCAACGTT
190	200	210	220	230	240
TCTGGCAGAC	CCTACAATGG	TTTCGCTTCC	CATTCTTCC	CCAATGCTCC	TATCTACAAAC
250	260	270	280	290	300
GACCGTGAAC	GCCTCCAGAT	TTACATCTCT	GATGCTGGTA	TTCTAGCCGT	CTGTTATGGT
310	320	330	340	350	360
CTTTACCGTT	ACGCTGTTGC	ACAAGGACTA	GCCTCAATGA	TCTGTCTAAA	CGGAGTTCCG
370	380	390	400	410	420
CTTCTGATAG	TTAACTTTT	CCTCGTCTTG	ATCACTTACT	TACAACACAC	TCACCCCTGCG
430	440	450	460	470	480
TTGCCCTCACT	ATGATTTCATC	AGAGTGGGAT	TGGCTTAGAG	GAGCTTTAGC	TACTGTAGAC
490	500	510	520	530	540
AGAGACTATG	GAATCTTGAA	CAAGGTGTTTC	CATAAACATCA	CAGACACCCA	CGTCGCACAC
550					
CACT					

Figure 6

09/117921

PCT/US97/02187

WO 97/30582

9/15




FIG. 7

10/15

AT GAA GCT TTA TAA GAA TTT AGT TTT CTC TGG TGA CAG AGA AAT TNT	47
GTC AAT TGG TAG TGA CAG TTG AAG CAA CAG GAA CAA CAA GGA TGG TTG	95
GTG NTG ATG CTG ATG TGG GA TGT GTT ATT CAT CAA ATA CTA AAT ACT	143
ACA TTA CTT GTT GCT GCC TAC TTC TCC TAT TTC CTC CGC CAC CCA TTT	191
TGG ACC CAC GAN CCT TCC ATT TAA ACC CTC TCT CGT GCT ATT CAC CAG	239
AAG AGA AGC CAA GAG AGA GAG AGA GAG AAT GTT CTG AGG ATC ATT GTC	287
TTC TTC ATC GTT ATT AAC GTA AGT TTT TTT TGA CCA CTC ATA TCT AAA	335
ATC TAG TAC ATG CAA TAG ATT AAT GAC TGT TCC TTC TTT TGA TAT TTT	383
Met Gly Ala Gly Gly Arg Ile Met Val Thr	10
CAG CTT CTT GAA TTC AAG ATG GGT GCT GGT GGA AGA ATA ATG GTT ACC	431
Pro Ser Ser Lys Lys Ser Glu Thr Glu Ala Leu Lys Arg Gly Pro Cys	26
CCC TCT TCC AAG AAA TCA GAA ACT GAA GCC CTA AAA CGT GGA CCA TGT	479
Glu Lys Pro Pro Phe Thr Val Lys Asp Leu Lys Lys Ala Ile Pro Gln	42
GAG AAA CCA CCA TTC ACT GTT AAA GAT CTG AAG AAA GCA ATC CCA CAG	527
His Cys Phe Lys Arg Ser Ile Pro Arg Ser Phe Ser Tyr Leu Leu Thr	58
CAT TGT TTC AAG CGC TCT ATC CCT CGT TCT TTC TCC TAC CTT CTC ACA	575
Asp Ile Thr Leu Val Ser Cys Phe Tyr Tyr Val Ala Thr Asn Tyr Phe	74
GAT ATC ACT TTA GTT TCT TGC TTC TAC TAC GTT GCC ACA AAT TAC TTC	623
Ser Leu Leu Pro Gln Pro Leu Ser Thr Tyr Leu Ala Trp Pro Leu Tyr	90
TCT CTT CCT CAG CCT CTC TCT ACT TAC CTA GCT TGG CCT CTC TAT	671
Trp Val Cys Gln Gly Cys Val Leu Thr Gly Ile Trp Val Ile Gly His	106
TGG GTA TGT CAA GGC TGT GTC TTA ACC GGT ATC TGG GTC ATT GGC CAT	719
Glu Cys Gly His His Ala Phe Ser Asp Tyr Gln Trp Val Asp Asp Thr	122
GAA TGT GGT CAC CAT GCA TTC AGT GAC TAT CAA TGG GTA GAT GAC ACT	767
Val Gly Phe Ile Phe His Ser Phe Leu Leu Val Pro Tyr Phe Ser Trp	138
GTT GGT TTT ATC TTC CAT TCC TTC CTT CTC GTC CCT TAC TTC TCC TGG	815
Lys Tyr Ser His Arg Arg His His Ser Asn Asn Gly Ser Leu Glu Lys	154
AAA TAC AGT CAT CGT CAC CAT TCC AAC AAT GGA TCT CTC GAG AAA	863
Asp Glu Val Phe Val Pro Pro Lys Lys Ala Ala Val Lys Trp Tyr Val	170
GAT GAA GTC TTT GTC CCA CCG AAG AAA GCT GCA GTC AAA TGG TAT GTT	911
Lys Tyr Leu Asn Asn Pro Leu Gly Arg Ile Leu Val Leu Thr Val Gln	186
AAA TAC CTC AAC AAC CCT CTT GGA CGC ATT CTG GTG TTA ACA GTT CAG	959

Figure 8A
SUBSTITUTE SHEET (RULE 26)

Phe Ile Leu Gly Trp Pro Leu Tyr Leu Ala Phe Asn Val Ser Gly Arg	202
TTT ATC CTC GGG TGG CCT TTG TAT CTA GCC TTT AAT GTA TCA GGT AGA	1007
Pro Tyr Asp Gly Phe Ala Ser His Phe Phe Pro His Ala Pro Ile Phe	218
CCT TAT GAT GGT TTC GCT TCA CAT TTC CCT CAT GCA CCT ATC TTT	1055
Lys Asp Arg Glu Arg Leu Gln Ile Tyr Ile Ser Asp Ala Gly Ile Leu	234
AAA GAC CGA GAA CGC CTC CAG ATA TAC ATC TCA GAT GCT GGT ATT CTA	1103
Ala Val Cys Tyr Gly Leu Tyr Arg Tyr Ala Ala Ser Gln Gly Leu Thr	250
GCT GTC TGT TAT GGT CTT TAC CGT TAC GCT GCT TCA CAA GGA TTG ACT	1151
Ala Met Ile Cys Val Tyr Gly Val Pro Leu Leu Ile Val Asn Phe Phe	266
GCT ATG ATC TGC GTC TAT GGA GTA CCG CTT TTG ATA GTG AAC TTT TTC	1199
Leu Val Leu Val Thr Phe Leu Gln His Thr His Pro Ser Leu Pro His	282
CTT GTC TTG GTA ACT TTC TTG CAG CAC ACT CAT CCT TCG TTA CCT CAT	1247
Tyr Asp Ser Thr Glu Trp Glu Trp Ile Arg Gly Ala Leu Val Thr Val	298
TAT GAT TCA ACC GAG TGG GAA TGG ATT AGA GGA GCT TTG GTT ACG GTA	1295
Asp Arg Asp Tyr Gly Ile Leu Asn Lys Val Phe His Asn Ile Thr Asp	314
GAC AGA GAC TAT GGA ATA TTG AAC AAG GTG TTC CAT AAC ATA ACA GAC	1343
Thr His Val Ala His His Leu Phe Ala Thr Ile Pro His Tyr Asn Ala	330
ACA CAT GTG GCT CAT CAT CTC TTT GCA ACT ATA CCG CAT TAT AAC GCA	1391
Met Glu Ala Thr Glu Ala Ile Lys Pro Ile Leu Gly Asp Tyr Tyr His	346
ATG GAA GCT ACA GAG GCG ATA AAG CCA ATA CTT GGT GAT TAC TAC CAC	1439
Phe Asp Gly Thr Pro Trp Tyr Val Ala Met Tyr Arg Glu Ala Lys Glu	362
TTC GAT GGA ACA CCG TGG TAT GTG GCC ATG TAT AGG GAA GCA AAG GAG	1487
Cys Leu Tyr Val Glu Pro Asp Thr Glu Arg Gly Lys Lys Gly Val Tyr	378
TGT CTC TAT GTA GAA CCG GAT ACG GAA CGT GGG AAG AAA GGT GTC TAC	1535
Tyr Tyr Asn Asn Lys Leu	384
TAT TAC AAC AAT AAG TTA TGA GGC TGA TAG GGC GAG AGA AGT GCA ATT	1583
ATC AAT CTT CAT TTC CAT GTT TTA GGT GTC TTG TTT AAG AAG CTA TGC	1631
TTT GTT TCA ATA ATC TCA GAG TCC ATN TAG TTG TGT TCT GGT GCA TTT	1679
TGC CTA GTT ATG TGG TGT CGG AAG TTA GTG TTC AAA CTG CTT CCT GCT	1727
GTG CTG CCC AGT GAA GAA CAA GTT TAC GTG TTT AAA ATA CTC GGA ACG	1775
AAT TGA CCA CAA NAT ATC CAA AAC CGG CTA TCC GAA TTC CAT ATC CGA	1823
AAA CCG GAT ATC CAA ATT TCC AGA GTA CTT AG	1855

Figure 8B

12/15

		10	20	30	40	50		
LFFAH12	1	MGAGGRIM--	--VTPSSKKs	--ETEALKRG	PCEKPPFTVK	DLKKAIPQHC	50	
FAH12	1	MGGGGRMSTV	ITSNNSEKKG	--GSSHLSKRA	PHTKPPFTLG	DLKRAIPPHC	50	
ATFAD2	1	MGAGGRMP--	--VPTSSKKs	--ETDTTKRV	PCEKPPFSVG	DLKKAIPPHC	50	
BNFAD2	1	MGAGGRMO--	--VSPPSKKS	--ETONIKRV	PCETPPFTVG	ELKKAIPPHC	50	
GMFAD2-1	1	MGLA-KETTM	GGRGRVAKVE	VQGKKPLSRV	PNTKPPFTVG	QLKKAIPPHC	50	
GMFAD2-2	1	MGAGGR----	TDVPPANRKS	--EVDPKRV	PFEKPQFSLs	QIKKAIPPHC	50	
ZMFAD2	1	MGAGGRMTEK	EREKQEQLAR	ATGGAAMQRS	PVEKPPFTLG	QIKKAIPPHC	50	
RCFAD2	1	-----	-----	-----	-----	-----	50	
		60	70	80	90	100		
LFFAH12	51	FKRSIPRSFS	YLLTDITLVS	CFYYVATNYF	SLLPQPLSTY	LAWPLYWVCQ	100	
FAH12	51	FERSFVRSFS	YVAYDVCLSF	LFYSIATNFF	PYISSPLS-Y	VAWLVYWLFO	100	
ATFAD2	51	FKRSIPRSFS	YLISDIIIAS	CFYYVATNYF	SLLPQPLS-Y	LAWPLYWACQ	100	
BNFAD2	51	FKRSIPRSFS	HLIWDIIIAS	CFYYVATTYF	PLLPNPLS-Y	FAWPLYWACQ	100	
GMFAD2-1	51	FQRSLLTSFS	YVVYDLSFAF	IFY-IATTYF	HLLPQFSL-L	IAWPIYWVLQ	100	
GMFAD2-2	51	FORSVLRSFS	YVVYDLTIAF	CLYYVATHYF	HLLPGPLS-F	RGMAIYWAVQ	100	
ZMFAD2	51	FERSVLKSFS	YVVHDLVIAA	ALLYFALAI	PALPSPLR-Y	AAWPLYWIAQ	100	
RCFAD2	51	-----	-----	-----	-----	-----	100	
		110	120	130	140	150		
LFFAH12	101	GCVLTGIVVI	GHECGHHAFs	DYQWVDDTVG	FIFHSFLLVP	YFSWKYSHRR	150	
FAH12	101	GCILTGLVVI	GHECGHHAFs	EYOLADDIVG	LIVHSALLVP	YFSWKYSHRR	150	
ATFAD2	101	GCVLTGIVVI	AHECGHHAFs	DYQWLDDTVG	LIFHSFLLVP	YFSWKYSHRR	150	
BNFAD2	101	GCVLTGIVVI	AHECGHAAFs	DYQWLDDTVG	LIFHSFLLVP	YFSWKYSHRR	150	
GMFAD2-1	101	GCLLTGVWVI	AHECGHHAFs	KYQWVDDVVG	LTLHSTLLVP	YFSWKISHRR	150	
GMFAD2-2	101	GCILTGVWVI	AHECGHHAFs	DYQLLDDIVG	LILHSALLVP	YFSWKYSHRR	150	
ZMFAD2	101	G-----	-----AFS	DYSLLDDVVG	LVLHSSLMVP	YFSWKYSHRR	150	
RCFAD2	101	-----	WVM	AHDCGHHAFs	DYQLLDDVVG	LILHSCLLVP	YFSWKHSHRR	150
		160	170	180	190	200		
LFFAH12	151	HHSNNGSLEK	DEVFVPPKKA	AVKWYVKYL-	NNPLGRILVL	TVQFILGWPL	200	
FAH12	151	HHSNIGSLER	DEVFVPKSKS	KISWYSKYS-	NNPPGRVLTL	AATLLLGWPL	200	
ATFAD2	151	HHSNTGSLER	DEVFVPKQKS	AIKWYKGKL-	NNPLGRIMML	TVQFVLGWPL	200	
BNFAD2	151	HHSNTGSLER	DEVFVPR-RS	QTSSGTAST-	STTFGRVTML	TVQFTLGWPL	200	
GMFAD2-1	151	HHSNTGSLDR	DEVFVPKPKS	KVAWSKYL-	NNPLGRAVSL	LVTLTIGWPM	200	
GMFAD2-2	151	HHSNTGSLER	DEVFVPKQKS	CIKWYSKYL-	NNPPGRVLTL	AVTTLTGWPL	200	
ZMFAD2	151	HHSNTGSLER	DEVFVPKKKE	ALPWYTPVYY	NNPVGRVVHI	VVOLTLGWPL	200	
RCFAD2	151	HHSNTGSLER	DEVFVPKKKS	SIRWYSKYL-	NNPPGRIMTI	AVTLSLGWPL	200	
		210	220	230	240	250		
LFFAH12	201	YLAFNVSGRP	YDG-FASHFF	PHAPIFKDRE	RLQIYISDAG	I LAVCYGLYR	250	
FAH12	201	YLAFNVSGRP	YDR-FACHYD	PYGPIFSERE	RLQIYIADLG	I FATTFLYQ	250	
ATFAD2	201	YLAFNVSGRP	YDG-FACHFF	PNAPIYNDRE	RLQIYLSDAG	I LAVCFGGLYR	250	
BNFAD2	201	YLAFNVSGRP	YDGGFACHFH	PNAPIYNDRE	RLQIYISDAG	I LAVCYGLLP	250	
GMFAD2-1	201	YLAFNVSGRP	YDS-FASHYH	PYAPIYSNRE	RLLIYVSDVA	LFSVTYSLYR	250	
GMFAD2-2	201	YLALNVSGRP	YDR-FACHYD	PYGPIYSDRE	RLQIYISDAG	V LAVVYGLFR	250	
ZMFAD2	201	YLATNASGRP	YPR-FACHFD	PYGPIYNDRE	RAQIFVSDAG	V VAVAFLGLYK	250	
RCFAD2	201	YLAFNVSGRP	YDR-FACHYD	PYGPIYNDRE	RIEIFISDAG	V LAVTFGLYO	250	

Figure 9A

09/117921

PCT/US97/02187

WO 97/30582

13/15

		260	270	280	290	300	
LFFAH12	251	YAASOGLTAM	ICVYGVPLLI	VNFFLVLVTF	LOHTHPSLPH	YDSTEWEWIR	300
FAH12	251	ATMAKGLAWV	MRIYGVPLLI	VNCFLVMITY	LOHTHPAIPR	YGSSEWDWLR	300
ATFAD2	251	YAAAOQGMASM	ICLYGVPLLI	VNAFLVLITY	LOHTHPSLPH	YOSSEWDWLR	300
BNFAD2	251	YAAVQGVASM	VCFLRVPLLI	VNGFLVLITY	LOHTHPSLPH	YOSSEWDWLR	300
GMFAD2-1	251	VATLKGLVWL	LCVYGVPLLI	VNGFLVTITY	LOHTHFALPH	YOSSEWDWLK	300
GMFAD2-2	251	LAMAKGLAWV	VCVYGVPLLV	VNGFLVLITF	LOHTHPALPH	YTSSSEWDWLR	300
ZMFAD2	251	LAAAFGVWWV	VRVYAVPLLI	VNAWLVLITY	LOHTHPSLPH	YOSSEWDWLR	300
RCFAD2	251	LAIAKGLAWV	VCVYGVPLLV	VNSFLVLITF	LOHTHPALPH	YOSSEWDWLR	300
		310	320	330	340	350	
LFFAH12	301	GALTVDRDY	GILNKVFHN	TDTVAHHLF	ATIPHYNAM	ATEAIKPILG	350
FAH12	301	GAMTVDRDY	GVLNKVFHN	ADTHVAHHLF	ATVPHYHAME	ATKAIKPIMG	350
ATFAD2	301	GALATVDRDY	GILNKVFHN	TDTVAHHLF	STMPHYHAME	ATKAIKPILG	350
BNFAD2	301	GALATVDRDY	GILNQGFHN	TOTHEAHLF	STMPHYHAME	ATKAIKPILG	350
GMFAD2-1	301	GALATMDRDY	GILNKVFHHI	TDTVAHHLF	STMPHYHAME	ATNAIKPILG	350
GMFAD2-2	301	GALATVDRDY	GILNKVFHN	TDTVAHHLF	STMPHYHAME	ATKAIKPILG	350
ZMFAD2	301	GALATMDRDY	GILNRVFHN	TDTVAHHLF	STMPHYHAME	ATKAIRPILG	350
RCFAD2	301	GALATVDRDY	GILNKVFHN	TDTQVAHHLF	-----	-----	350
		360	370	380	390	400	
LFFAH12	351	DYYHFDGTPW	YVAMYREAKE	CLYVEPDT	GKKGVYYYNN	K-L.....	400
FAH12	351	EYYRYDGTPF	YKALWREAKE	CLFVEPDEGA	PTQGVFWYRN	KY-.....	400
ATFAD2	351	DYYQFDGTPW	YVAMYREAKE	CIYVEPDREG	DKKGVYWYNN	K-L.....	400
BNFAD2	351	EYYQFDGTPV	VKAMWREAKE	CIYVEPDRQG	EKKGVFWYNN	KL*.....	400
GMFAD2-1	351	EYYQFDDTPF	YKALWREARE	CLYVEPDEGT	SEKGVYWYRN	KY-.....	400
GMFAD2-2	351	EYYRFDETPF	VKAMWREARE	CIYVEPDQST	ESKGVFWYNN	KL-.....	400
ZMFAD2	351	DYYHFDPTPV	AKATWREAGE	CIYVEPE--	DRKGVFWYNK	KF*.....	400

Figure 9B

09/11792T
PCT/US97/02187

WO 97/30582

14/15





FIG.10



Plasmid name: pSLJ44026

Plasmid size: 25.70 kb

Constructed by: Jonathon Jones

Construction date: 1992

Comments/References: Transgenic Research 1,285-297 (1992)

Figure 11

FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PM & S
FORM

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED PRODUCTION OF HYDROXYLATED FATTY ACIDS IN GENETICALLY MODIFIED PLANTS

the specification of which (CHECK applicable BOX(ES))
 is attached hereto.
 X was filed on August 6, 1998 as U.S. Application No. 09/117,921
 was filed as PCT International Application No. PCT/ US97/02187 on February 6, 1997

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S) Number	Country	Day/MONTH/Year Filed	Date first Laid-open or Published	Date Patented or Granted	Priority Claimed Yes	Priority Claimed No
--	---------	----------------------	-----------------------------------	--------------------------	-------------------------	------------------------

I hereby claim domestic priority benefit under 35 U.S.C. 119/120/365 of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S) Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status	Priority Claimed Yes	Priority Claimed No
PCT/US97/02187	06/February/1997	pending, abandoned, patented	X	
08/597,313	06/February/1996	Pending	X	
08/530,862	20/September/1995	Pending	X	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Madison & Sutro LLP, Intellectual Property Group, 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington, D.C. 20005-3918, telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	David W. Brinkman	20817	G. Paul Edgell	24238	Richard H. Zaitlen	27248
Raymond F. Lippitt	17519	Donald J. Bird	25323	Lynn E. Eccleston	35864	Roger R. Wise	31204
G. Lloyd Knight	17698	Peter W. Gowdey	25872	Timothy J. Klima	34852	Jay M. Finkelstein	21082
Carl G. Love	18781	Dale S. Lazar	28872	David A. Jakopin	32995	Anita M. Kirkpatrick	32617
Edgar H. Martin	20534	Paul E. White, Jr.	32011	Mark G. Paulson	30793		
William K. West, Jr.	22057	Glenn J. Perry	28458	Stephen C. Glazier	31361		
Kevin E. Joyce	20508	Kendrew H. Colton	30368	Paul F. McQuade	31542		
George M. Sirilla	18221	Michelle N. Lester	32331	Ruth N. Morduch	31044		

(1) INVENTOR'S SIGNATURE:

Date:

Pierre		BROUN	
First	Middle Initial	Family Name	
Residence	Burlingame	California	France
Post Office Address	City State/Foreign Country Country of Citizenship		
(include Zip Code)	1249 Capuchino, Burlingame, California France		

(2) INVENTOR'S SIGNATURE:

Date: 10/3/98

Frank		van de LOO	
First	Middle Initial	Family Name	
Residence	Weston LYONS	Australia	Australia
Post Office Address	City State/Foreign Country Country of Citizenship		
(include Zip Code)	11 Fowles Street, Weston, ACT 2611, Australia 3 RUSDEN PL, LYONS ACT 2606, AUSTRALIA		

(FOR ADDITIONAL INVENTORS, check box to attach PAT 116-2 same information for each re signature, name, date, citizenship, residence and address.)

DECLARATION AND POWER OF ATTORNEY
 (continued)
ADDITIONAL INVENTORS

(3) INVENTOR'S SIGNATURE:

Date:

Sekhar	S.	BODDUPALLI
First	Middle Initial	Family Name
Residence	Manchester	Missouri
City	State/Foreign Country	Country of Citizenship
Post Office Address (include Zip Code)	572 Enchanted Parkway, Manchester, Missouri 63021	

(4) INVENTOR'S SIGNATURE:

Date: 9/26/98

Chris	SOMERVILLE	
First	Middle Initial	Family Name
Residence	Portola Valley	California
City	State/Foreign Country	Country of Citizenship
Post Office Address (include Zip Code)	5 Valley Oak, Portola Valley, California 94028	

(5) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Post Office Address (include Zip Code)			

(6) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Post Office Address (include Zip Code)			

(7) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Post Office Address (include Zip Code)			

(8) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Post Office Address (include Zip Code)			

(9) INVENTOR'S SIGNATURE:

Date:

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Post Office Address (include Zip Code)			

FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS

RULE 63 (37 C.F.R. 1.63)
DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PM & S
FORM

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below), of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED PRODUCTION OF HYDROXYLATED FATTY ACIDS IN GENETICALLY MODIFIED PLANTS

the specification of which (CHECK applicable BOX(ES))
 X → is attached hereto.
 BOX(ES) → was filed on August 6, 1998 as U.S. Application No. 09/117,921
 → was filed as PCT International Application No. PCT/ US97/02187 on February 6, 1997

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S)	Date first Laid-open or Published	Date Patented or Granted	Priority Claimed	
Number	Country	Day/Month/Year Filed	Yes	No

I hereby claim domestic priority benefit under 35 U.S.C. 119/120/365 of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S)	Status	Priority Claimed		
Application No. (series code/serial no.)	Day/Month/Year Filed	pending, abandoned, patented	Yes	No
PCT/US97/02187	06/February/1997	pending, abandoned, patented	X	
08/597,313	06/February/1996	Pending	X	
08/530,862	20/September/1995	Pending		X

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Madison & Sutro LLP, Intellectual Property Group, 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington, D.C. 20005-3918, - telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	David W. Brinkman	20817	G. Paul Edgell	24238	Richard H. Zaitlen	27248
Raymond F. Lippitt	17519	Donald J. Bird	25323	Lynn E. Eccleston	35861	Roger R. Wise	3T204
G. Lloyd Knight	17698	Peter W. Gowdey	25872	Timothy J. Klima	34852	Jay M. Finkelstein	21082
Carl G. Love	18781	Dale S. Lazar	28872	David A. Jakopin	32995	Anita M. Kirkpatrick	32617
Edgar H. Martin	20534	Paul E. White, Jr.	32011	Mark G. Paulson	30793		
William K. West, Jr.	2205Z	Glenn J. Perry	28458	Stephen C. Glazier	31361		
Kevin E. Joyce	20508	Kendrew H. Colton	30368	Paul F. McQuade	31542		
George M. Sirilla	18221	Michelle N. Lester	32331	Ruth N. Morduch	31044		

(1) INVENTOR'S SIGNATURE:

<u>Pierre</u>	<u>BROUN</u>		
First	Middle Initial	Family Name	
Residence	Burlingame	California	France
City	State/Foreign Country		
Post Office Address	Country of Citizenship		
(include Zip Code)	1249 Capuchino, Burlingame, California		
	94010		

Date: 10-6-98

(2) INVENTOR'S SIGNATURE:

<u>Frank</u>	<u>van de LOO</u>		
First	Middle Initial	Family Name	
Residence	Weston	Australia	Australia
City	State/Foreign Country		
Post Office Address	Country of Citizenship		
(include Zip Code)	11 Fowles Street, Weston, ACT 2611, Australia		

(FOR ADDITIONAL INVENTORS, check box to attach PAT 116-2 same information for each re signature, name, date, citizenship, residence and address.)

DECLARATION AND POWER OF ATTORNEY

(continued)

ADDITIONAL INVENTORS

(3) INVENTOR'S SIGNATURE:

R. Sekhar

Date:

10/21/98

Sekhar	S.	BODDUPALLI	
Residence	First Manchester	Middle Initial / / / / /	Family Name India
Post Office Address (include Zip Code)	City 572 Enchanted Parkway, Manchester, Missouri 63021		State/Foreign Country Country of Citizenship

(4) INVENTOR'S SIGNATURE:

Chris

Date:

Chris	SOMERVILLE		
Residence	First Portola Valley	Middle Initial <i>CA</i>	Family Name United States
Post Office Address (include Zip Code)	City 5 Valley Oak, Portola Valley, California 94028		State/Foreign Country Country of Citizenship

(5) INVENTOR'S SIGNATURE:

Date:

	First	Middle Initial	Family Name
Residence			
Post Office Address (include Zip Code)	City		State/Foreign Country Country of Citizenship

(6) INVENTOR'S SIGNATURE:

Date:

	First	Middle Initial	Family Name
Residence			
Post Office Address (include Zip Code)	City		State/Foreign Country Country of Citizenship

(7) INVENTOR'S SIGNATURE:

Date:

	First	Middle Initial	Family Name
Residence			
Post Office Address (include Zip Code)	City		State/Foreign Country Country of Citizenship

(8) INVENTOR'S SIGNATURE:

Date:

	First	Middle Initial	Family Name
Residence			
Post Office Address (include Zip Code)	City		State/Foreign Country Country of Citizenship

(9) INVENTOR'S SIGNATURE:

Date:

	First	Middle Initial	Family Name
Residence			
Post Office Address (include Zip Code)	City		State/Foreign Country Country of Citizenship